Toxicology – Dantrolene

Core Concept

Dantrolene is a direct-acting skeletal muscle relaxant and the specific treatment for malignant hyperthermia (MH).

Its major action is to reduce abnormal calcium release from skeletal-muscle sarcoplasmic reticulum.

In toxicology, dantrolene has also been used as an adjunct for severe muscle rigidity and hyperthermia in selected conditions such as neuroleptic malignant syndrome (NMS). However, older recommendations for routine use in serotonin syndrome, stimulant poisoning, carbon monoxide poisoning, or MAOI poisoning are not supported as standard modern therapy.

Mechanism of Action

Dantrolene acts primarily on skeletal muscle rather than the CNS.

It inhibits excessive calcium release through the skeletal-muscle ryanodine receptor (RyR1).

The sequence is:

↓ sarcoplasmic-reticulum Ca²⁺ release → ↓ intracellular Ca²⁺ → ↓ excitation–contraction coupling → ↓ muscle contraction and heat production

This explains its effectiveness in malignant hyperthermia.

Effect on Muscle

Dantrolene decreases the strength of skeletal-muscle contraction.

This can reduce:

• Rigidity
• Muscle-generated heat
• Excessive metabolic activity
• Rhabdomyolysis associated with sustained contraction

However, excessive effect can also produce clinically important muscle weakness.

Malignant Hyperthermia

Malignant hyperthermia is a potentially fatal hypermetabolic skeletal-muscle disorder occurring in genetically susceptible individuals after exposure to certain anesthetic triggers.

Important triggers include:

• Volatile inhalational anesthetics
• Succinylcholine

Abnormal RyR1-mediated calcium release causes uncontrolled skeletal-muscle metabolism.

Clinical Features of Malignant Hyperthermia

Possible findings include:

• Rapidly increasing end-tidal CO₂
• Tachycardia
• Muscle rigidity
• Masseter rigidity
• Metabolic acidosis
• Respiratory acidosis
• Hyperkalemia
• Rhabdomyolysis
• Rising creatine kinase
• Myoglobinuria
• Dysrhythmias
• Hyperthermia

A major high-yield point:

Hyperthermia may be a relatively late finding.

Do not wait for an extreme temperature before considering malignant hyperthermia.

Why CO₂ Is Important

Rapidly increasing CO₂ production is often an early manifestation of the hypermetabolic state.

During anesthesia, an otherwise unexplained rise in end-tidal CO₂ despite adequate ventilation is an important warning sign.

This may precede dramatic hyperthermia.

Treatment of Malignant Hyperthermia

Immediate priorities include:

• Stop triggering anesthetic agents.
• Give IV dantrolene promptly.
• Hyperventilate with high-concentration oxygen.
• Actively cool the patient when significantly hyperthermic.
• Treat hyperkalemia.
• Correct severe acidosis when appropriate.
• Treat dysrhythmias.
• Manage rhabdomyolysis and renal complications.
• Monitor closely for recurrence.

Dantrolene is central to treatment but does not replace resuscitative and supportive care.

Dantrolene Administration Principle

Dantrolene is administered promptly and repeatedly according to the patient’s clinical response until the hypermetabolic syndrome is controlled.

Because available formulations differ in concentration and reconstitution requirements, current product-specific malignant-hyperthermia protocols should be followed rather than older fixed preparation instructions.

Exact emergency dosing is best taken from the current institutional/MH protocol.

Recurrence of Malignant Hyperthermia

Symptoms can recur after initial stabilization.

Therefore, successful initial treatment does not mean monitoring can immediately stop.

Continued observation and additional dantrolene may be required according to the patient’s course.

Monitoring After Malignant Hyperthermia

Follow:

• Core temperature
• Continuous ECG
• End-tidal CO₂ when ventilated
• Blood pressure
• Potassium
• Blood gas
• Creatine kinase
• Renal function
• Urine output
• Evidence of myoglobinuria
• Coagulation studies in severe disease

Severe MH can cause multiorgan complications.

Neuroleptic Malignant Syndrome

NMS is usually associated with:

• Dopamine receptor blockade

or

• Abrupt withdrawal/reduction of dopaminergic therapy

Typical manifestations include:

• Hyperthermia
• Severe generalized rigidity
• Altered mental status
• Autonomic instability
• Elevated CK
• Rhabdomyolysis

Dantrolene in NMS

Dantrolene may be considered as an adjunct in severe NMS, particularly when prominent rigidity and hyperthermia are present.

However, unlike malignant hyperthermia:

Dantrolene is not a universally required or uniquely definitive antidote for NMS.

Core treatment remains:

• Stop the causative medication.
• Provide aggressive supportive care.
• Correct fluid and electrolyte abnormalities.
• Control severe hyperthermia.
• Treat complications.

Selected severe cases may also involve agents such as bromocriptine or amantadine and specialist-directed therapy.

Malignant Hyperthermia vs NMS

Although both can cause rigidity and hyperthermia, they are different syndromes.

Malignant Hyperthermia

Usually:

• Triggered by certain anesthetics/succinylcholine
• Rapid onset
• Direct skeletal-muscle calcium dysregulation
• Dantrolene is specific treatment

NMS

Usually:

• Related to dopamine blockade or dopaminergic withdrawal
• Evolves over a longer period
• CNS dopamine dysfunction is central
• Dantrolene is an optional adjunct rather than universally required

Serotonin Syndrome

The older source proposed dantrolene for serotonin syndrome.

This is not standard modern treatment.

Serotonin syndrome is characterized particularly by:

• Agitation
• Hyperreflexia
• Clonus
• Tremor
• Autonomic hyperactivity
• Hyperthermia in severe cases

Treatment emphasizes:

• Stop serotonergic drugs.
• Benzodiazepines for agitation and muscle activity.
• Aggressive cooling.
• IV fluids/supportive care.
• Cyproheptadine in selected cases.

Severe Serotonin-Syndrome Hyperthermia

Extreme hyperthermia is largely generated by excessive muscular activity.

In severe cases, management may require:

• Airway control
• Deep sedation
• Nondepolarizing neuromuscular paralysis
• Aggressive external cooling

Dantrolene has not demonstrated a sufficiently established benefit to be routine therapy.

Stimulant Toxicity

Older reports suggested dantrolene for hyperthermia caused by:

• Cocaine
• Amphetamines

Modern treatment instead emphasizes:

• Benzodiazepine sedation
• Rapid external cooling
• IV supportive care
• Treatment of seizures
• Management of cardiovascular complications

If life-threatening hyperthermia persists because of uncontrolled muscle activity, advanced airway management and neuromuscular paralysis may be necessary.

Dantrolene is not routinely recommended simply because stimulant toxicity causes hyperthermia.

MAOI Poisoning

MAOI toxicity can produce:

• Agitation
• Hyperthermia
• Hypertension or hypotension
• Neuromuscular abnormalities
• Seizures
• Serotonergic features

Management is predominantly aggressive supportive care.

Dantrolene is not a routine antidote for MAOI poisoning.

Carbon Monoxide Poisoning

The historical suggestion that dantrolene may treat carbon monoxide poisoning is not part of standard modern management.

CO poisoning is managed with:

• Immediate removal from exposure
• High-concentration oxygen
• Supportive care
• Hyperbaric oxygen in selected severe cases

Dantrolene does not reverse carboxyhemoglobin formation or the fundamental toxic mechanism of CO.

When Dantrolene Is Unlikely to Help

Dantrolene is most logical when excessive skeletal-muscle calcium release and contraction are major drivers of the syndrome.

It does not directly correct hyperthermia caused primarily by:

• Reduced sweating in anticholinergic poisoning
• Environmental heat exposure
• Salicylate-induced metabolic hyperthermia
• Thyroid hormone excess
• Infection or fever

The cause of hyperthermia determines treatment.

Dantrolene Is Not an Antipyretic

Dantrolene does not lower temperature by resetting the hypothalamic temperature set point.

Its benefit in MH comes from reducing skeletal-muscle heat generation.

Similarly, conventional antipyretics such as acetaminophen are generally ineffective for toxicologic hyperthermia because these syndromes are not ordinary fever.

Adverse Effects

Important adverse effects include:

• Muscle weakness
• Fatigue
• Dizziness
• Nausea
• Diarrhea
• Sedation
• Respiratory muscle weakness

In critically ill patients, additional weakness can complicate ventilation and recovery.

Hepatotoxicity

Dantrolene can cause liver injury.

Risk is primarily associated with longer-term oral therapy, rather than the short emergency courses used for malignant hyperthermia.

Potential abnormalities include:

• Elevated aminotransferases
• Hepatitis
• Rare severe hepatic injury

Liver function becomes particularly important with prolonged therapy.

Respiratory Effects

Because dantrolene weakens skeletal muscle, excessive treatment can worsen:

• Respiratory muscle weakness
• Ability to cough
• Ventilatory reserve

Patients with severe underlying neuromuscular or respiratory dysfunction therefore require careful monitoring.

Cardiovascular Considerations

Hemodynamic abnormalities can occur during severe illness or treatment.

An especially important interaction is with some calcium channel blockers, particularly verapamil, where combined use with dantrolene has been associated with serious cardiovascular effects and hyperkalemia.

This interaction is particularly relevant in malignant-hyperthermia management.

Pulmonary Edema – Historical Context

Older dantrolene formulations required substantial amounts of diluent, and large-volume administration could contribute to fluid burden.

Newer concentrated formulations may require considerably less volume.

Therefore, fluid-related complications depend partly on the formulation being used.

Pregnancy

The old FDA Category C classification is obsolete.

If malignant hyperthermia develops during pregnancy or around delivery, the maternal emergency requires prompt treatment.

Dantrolene should not be withheld when clinically necessary for malignant hyperthermia.

Chronic Dantrolene Therapy

Outside acute toxicology, oral dantrolene can be used for selected disorders involving chronic spasticity.

Long-term therapy differs substantially from emergency MH treatment and requires particular attention to:

• Liver function
• Muscle weakness
• Functional impairment
• Medication interactions

Important Modernization of the Older Source

Several older recommendations need correction:

• Malignant hyperthermia is the major established emergency indication for dantrolene.
• Dantrolene acts mainly through skeletal-muscle RyR1 inhibition, reducing sarcoplasmic-reticulum calcium release.
• Hyperthermia may occur late in MH; rising end-tidal CO₂, tachycardia, rigidity, acidosis, and hyperkalemia may appear earlier.
• Dantrolene can be considered in severe NMS but is an adjunct rather than an obligatory antidote.
• Dantrolene is not routine treatment for serotonin syndrome.
• It is not standard therapy for stimulant-induced hyperthermia, MAOI poisoning, or carbon monoxide poisoning.
• Severe serotonin or stimulant hyperthermia is managed primarily with sedation, aggressive cooling, and, when necessary, nondepolarizing neuromuscular paralysis.
• Dantrolene does not substitute for rapid external cooling or general critical care.
• Antipyretics do not effectively treat muscle-generated toxicologic hyperthermia.
• Modern dantrolene formulations differ, so historical reconstitution volumes and fixed preparation instructions should not be generalized.
• Hepatotoxicity is predominantly a concern with prolonged treatment rather than short emergency MH therapy.

Key Points

• Dantrolene is the specific drug treatment for malignant hyperthermia.
• It acts directly on skeletal muscle by reducing RyR1-mediated calcium release from the sarcoplasmic reticulum.
• This decreases muscle contraction, metabolism, and heat production.
• Malignant hyperthermia can initially present with rising end-tidal CO₂, tachycardia, rigidity, acidosis, and hyperkalemia before dramatic hyperthermia develops.
• Stop triggering anesthetics and administer dantrolene promptly when MH is suspected.
• Aggressive supportive care, cooling, electrolyte management, and treatment of rhabdomyolysis remain essential.
• MH can recur after initial control, so continued monitoring is necessary.
• Dantrolene may be considered as an adjunct for severe NMS, especially with marked rigidity and hyperthermia.
• It is not standard therapy for serotonin syndrome.
• It is not routinely indicated for cocaine/amphetamine hyperthermia, MAOI poisoning, carbon monoxide poisoning, anticholinergic hyperthermia, or heat stroke.
• Severe toxicologic hyperthermia caused by excessive muscle activity may require sedation, cooling, airway management, and nondepolarizing paralysis.
• Important adverse effects include muscle weakness and respiratory impairment.
• Hepatotoxicity is mainly associated with prolonged therapy.
• Dantrolene treats the muscular mechanism of MH; it is not a general-purpose treatment for every form of hyperthermia.

196. Toxicology – Cyanide Antidotes

Core Concept

The historical cyanide antidote kit contained:

• Amyl nitrite
• Sodium nitrite
• Sodium thiosulfate

The nitrites intentionally produce methemoglobin, which can bind cyanide, while sodium thiosulfate facilitates conversion of cyanide into the less toxic compound thiocyanate.

Modern practice has changed substantially. Hydroxocobalamin is generally preferred for serious suspected cyanide poisoning, particularly after smoke inhalation, because it binds cyanide without deliberately reducing the blood’s oxygen-carrying capacity.

Cyanide Toxicity – Mechanism

Cyanide primarily inhibits mitochondrial cytochrome c oxidase (Complex IV).

This prevents cells from effectively using oxygen for oxidative phosphorylation.

The sequence is:

Cytochrome oxidase inhibition → failure of oxidative phosphorylation → ATP depletion → cellular hypoxia despite available oxygen

The result is rapid histotoxic hypoxia.

Consequences of Cellular Respiratory Failure

Severe cyanide poisoning can cause:

• Marked lactic acidosis
• Altered mental status
• Seizures
• Hypotension
• Dysrhythmias
• Cardiovascular collapse
• Coma
• Cardiac arrest

The brain and cardiovascular system are particularly vulnerable because of their high energy requirements.

Important Exposure Sources

Potential sources include:

• Enclosed-space structural fires
• Cyanide salts
• Hydrogen cyanide gas
• Certain industrial processes
• Some laboratory chemicals
• Selected occupational exposures
• Excessive/prolonged sodium nitroprusside exposure
• Certain cyanogenic compounds

Clinical context is essential because cyanide concentrations are often not rapidly available.

Smoke Inhalation

Cyanide should be considered in a severely ill patient following an enclosed-space fire, particularly with:

• Altered mental status
• Hypotension
• Cardiovascular collapse
• Severe metabolic/lactic acidosis
• Soot or evidence of significant smoke exposure

However, smoke inhalation can simultaneously cause:

• Carbon monoxide poisoning
• Cyanide poisoning
• Thermal airway injury
• Pulmonary irritant injury

Therefore, multiple mechanisms may coexist.

Lactate as a Clinical Clue

A markedly elevated lactate after a compatible exposure can support the diagnosis of severe cyanide poisoning.

However:

Elevated lactate is not specific for cyanide.

Other causes include:

• Shock
• Seizures
• Severe hypoxia
• Sepsis
• Stimulant toxicity
• Other mitochondrial poisons

The diagnosis remains clinical and exposure-based.

Do Not Wait for a Cyanide Level

Cyanide testing is generally too slow to guide emergency treatment.

In a patient with a strongly compatible exposure and severe clinical toxicity:

Antidotal treatment should not be delayed while waiting for laboratory confirmation.

Immediate Management

Priorities include:

• Remove the patient from ongoing exposure without endangering rescuers.
• Support airway and ventilation.
• Give high-concentration oxygen when indicated.
• Treat seizures.
• Support circulation.
• Correct immediately life-threatening metabolic abnormalities.
• Administer an appropriate cyanide antidote when clinically indicated.

Antidotes complement rather than replace aggressive supportive care.

Modern Preferred Antidote – Hydroxocobalamin

Hydroxocobalamin is a vitamin B12 precursor that directly binds cyanide.

The reaction produces:

Cyanide + hydroxocobalamin → cyanocobalamin

Cyanocobalamin is substantially less toxic and is eliminated from the body.

Advantages of Hydroxocobalamin

A major advantage is that it:

Does not intentionally produce methemoglobinemia.

This is especially important in smoke-inhalation victims who may already have impaired oxygen delivery from:

• Carbon monoxide
• Pulmonary injury
• Hypoxemia

Hydroxocobalamin is therefore particularly useful when cyanide poisoning and carbon monoxide exposure may coexist.

Hydroxocobalamin Adverse Effects

Important effects include:

• Transient hypertension
• Red discoloration of skin
• Dark red urine
• Interference with some laboratory assays

The intense red coloration can also interfere with certain optical monitoring or laboratory technologies.

These effects should not be mistaken for worsening cyanide toxicity.

Historical Nitrite–Thiosulfate Antidote System

The traditional cyanide kit relied on two complementary mechanisms:

Nitrites

Produce methemoglobin.

Sodium thiosulfate

Provides sulfur substrate that assists conversion of cyanide to thiocyanate.

This strategy can still have selected roles, but it is no longer the preferred default approach in many emergency settings.

Sodium Nitrite – Mechanism

Sodium nitrite oxidizes hemoglobin iron:

Fe²⁺ → Fe³⁺

This converts hemoglobin into methemoglobin.

Methemoglobin can bind cyanide, forming cyanomethemoglobin and reducing the amount of cyanide available to inhibit mitochondrial cytochrome oxidase.

Problem With Nitrite Therapy

Methemoglobin cannot transport oxygen normally.

Therefore:

The antidote itself decreases functional oxygen-carrying capacity.

Excessive methemoglobinemia can produce:

• Cyanosis
• Headache
• Dyspnea
• Tachycardia
• Altered mental status
• Tissue hypoxia
• Cardiovascular instability

This creates an important therapeutic limitation.

Why Nitrites Are Concerning in Smoke Inhalation

A smoke-inhalation victim may already have substantial carboxyhemoglobin from carbon monoxide.

Giving nitrite can add methemoglobin.

The combination produces:

Carboxyhemoglobin + methemoglobin → further reduction in functional oxygen-carrying capacity

For this reason, deliberate methemoglobin formation is generally undesirable when significant carbon monoxide poisoning may coexist.

Hydroxocobalamin has largely solved this problem.

Amyl Nitrite

Historically, amyl nitrite was inhaled as a temporary measure while IV access was being established.

Its purpose was to produce methemoglobin rapidly.

This approach is now largely obsolete.

Priorities such as:

• Effective oxygenation
• Ventilation
• Circulatory support
• Rapid definitive antidotal therapy

are more important than attempting to create methemoglobinemia using inhaled amyl nitrite.

Sodium Thiosulfate

Sodium thiosulfate acts differently from nitrites.

It provides a sulfur donor that facilitates enzymatic detoxification of cyanide into thiocyanate.

Thiocyanate is much less toxic than cyanide and is primarily eliminated through the kidneys.

Advantages of Sodium Thiosulfate

Unlike nitrites, sodium thiosulfate:

• Does not intentionally produce methemoglobinemia
• Does not directly impair hemoglobin oxygen transport

It may be used as an adjunct in selected cyanide poisonings.

However, its onset is slower than direct cyanide-binding therapy, making it less attractive as the sole antidote in rapidly deteriorating severe poisoning.

Renal Failure and Thiocyanate

Thiocyanate depends substantially on renal elimination.

Therefore, significant renal dysfunction can result in accumulation.

Excess thiocyanate may produce:

• Nausea
• Weakness
• Confusion
• Neurologic abnormalities
• Other systemic manifestations

Renal function becomes particularly important when thiosulfate-based therapy or prolonged nitroprusside exposure is involved.

Hydroxocobalamin + Sodium Thiosulfate

In selected severe cyanide poisoning, sodium thiosulfate may be considered alongside hydroxocobalamin.

However, antidotal combinations and administration should follow current toxicology/poison-center protocols.

The key concept is that the two drugs use different mechanisms:

Hydroxocobalamin binds cyanide directly.

Thiosulfate promotes conversion to thiocyanate.

Sodium Nitroprusside and Cyanide

Sodium nitroprusside metabolism can release cyanide.

Risk increases with:

• High infusion rates
• Prolonged exposure
• Limited detoxification capacity
• Severe illness

Potential manifestations include:

• Unexplained metabolic/lactic acidosis
• Altered mental status
• Cardiovascular instability
• Apparent resistance to expected nitroprusside effects

Management includes stopping the exposure and treating clinically significant cyanide toxicity appropriately.

Cyanide and Hyperkalemia

Severe cyanide poisoning can be associated with metabolic derangements, but hyperkalemia is not sufficiently specific to serve as a defining diagnostic feature.

The more characteristic laboratory clue in severe acute poisoning is:

Marked lactic acidosis in the appropriate exposure setting.

Hydrogen Sulfide – Important Modern Correction

The historical cyanide kit was also proposed for hydrogen sulfide (H₂S) poisoning, particularly sodium nitrite therapy.

The rationale was that induced methemoglobin might bind sulfide.

However, modern evidence does not support routine nitrite-induced methemoglobinemia as established therapy for hydrogen sulfide poisoning.

Modern Hydrogen Sulfide Management

Treatment primarily consists of:

• Immediate removal from exposure by appropriately protected rescuers
• High-concentration oxygen
• Airway and ventilatory support
• Cardiovascular resuscitation
• Seizure management
• General critical care

Because hydrogen sulfide can incapacitate rescuers extremely rapidly, protected rescue is essential.

Use of specific antidotal strategies remains less established than treatment of cyanide poisoning.

Cyanide vs Hydrogen Sulfide

Both can inhibit cellular respiration and produce:

• Rapid collapse
• Severe neurologic dysfunction
• Cardiovascular failure
• Lactic acidosis

But they are distinct poisons, and evidence for cyanide antidotes should not automatically be extrapolated to hydrogen sulfide.

Methemoglobin Monitoring

If a methemoglobin-forming antidote is used, monitor:

• Methemoglobin concentration by co-oximetry
• Oxygenation
• Hemoglobin concentration
• Hemodynamics
• Mental status
• Acid-base status

Pulse oximetry alone cannot accurately quantify methemoglobinemia.

Why Anemia Matters

A patient with anemia already has reduced oxygen-carrying capacity.

Converting part of the remaining hemoglobin into methemoglobin can further compromise oxygen delivery.

Therefore, deliberate methemoglobinemia is particularly concerning in:

• Significant anemia
• Carbon monoxide poisoning
• Preexisting methemoglobinemia
• Severe pulmonary injury
• Other states of impaired oxygen delivery

Pregnancy

Severe maternal cyanide poisoning poses an immediate threat to both mother and fetus.

Pregnancy should therefore not delay necessary antidotal treatment.

The obsolete FDA pregnancy-category framework should not determine emergency management.

Monitoring Severe Cyanide Poisoning

Monitor:

• Airway and ventilation
• Oxygenation
• Continuous ECG
• Blood pressure
• Mental status
• Temperature
• Blood gas
• Lactate
• Electrolytes
• Renal function

When relevant, also measure:

• Carboxyhemoglobin
• Methemoglobin

Serial clinical reassessment is more useful than waiting for cyanide concentrations.

Important Modernization of the Older Source

Several major updates are necessary:

• The traditional amyl nitrite + sodium nitrite + sodium thiosulfate cyanide kit is no longer the preferred default antidotal strategy.
• Hydroxocobalamin is generally preferred for serious suspected cyanide poisoning, particularly after smoke inhalation.
• Hydroxocobalamin binds cyanide without intentionally causing methemoglobinemia.
• Nitrite therapy can impair oxygen delivery and is particularly problematic when carbon monoxide poisoning, anemia, or existing methemoglobinemia is present.
• Amyl nitrite pearls have little role in contemporary emergency treatment.
• Sodium thiosulfate remains a potential adjunct but acts more slowly.
• Laboratory confirmation of cyanide exposure should not delay antidotal therapy in a critically ill patient with a compatible exposure.
• Marked lactate elevation is an important clue but is not specific for cyanide.
• Routine prophylactic antidote administration to an asymptomatic exposed person is not automatically appropriate.
• The historical recommendation for routine sodium nitrite treatment of hydrogen sulfide poisoning is not established modern practice.
• Current hydrogen sulfide treatment emphasizes rapid protected rescue and aggressive supportive care.
• Historical fixed antidote regimens should be replaced by current product-specific emergency and poison-center protocols.

Key Points

• Cyanide inhibits mitochondrial cytochrome c oxidase, preventing effective cellular oxygen utilization.
• Severe poisoning causes histotoxic hypoxia and profound lactic acidosis.
• Rapid neurologic and cardiovascular collapse can occur.
• Do not wait for a cyanide level when severe poisoning is clinically suspected.
• Hydroxocobalamin is generally the preferred modern antidote.
• Hydroxocobalamin directly binds cyanide to form cyanocobalamin.
• It does not intentionally decrease oxygen-carrying capacity.
• This makes it especially useful in smoke-inhalation victims who may also have carbon monoxide poisoning.
• Sodium nitrite works by creating methemoglobin, which can bind cyanide.
• Excess methemoglobin itself impairs oxygen transport.
• Nitrites therefore require particular caution when oxygen delivery is already compromised.
• Sodium thiosulfate promotes conversion of cyanide to thiocyanate.
• Thiocyanate is primarily renally eliminated and can accumulate in renal failure.
• Amyl nitrite is largely obsolete in modern cyanide management.
• Smoke inhalation may simultaneously produce cyanide toxicity, carbon monoxide poisoning, and pulmonary injury.
• Routine nitrite therapy for hydrogen sulfide poisoning is not supported by strong modern evidence.
• Antidotes never replace aggressive airway, ventilation, oxygenation, seizure, and circulatory support.

196. Toxicology – Cyanide Antidotes

Core Concept

The historical cyanide antidote kit contained:

• Amyl nitrite
• Sodium nitrite
• Sodium thiosulfate

The nitrites intentionally produce methemoglobin, which can bind cyanide, while sodium thiosulfate facilitates conversion of cyanide into the less toxic compound thiocyanate.

Modern practice has changed substantially. Hydroxocobalamin is generally preferred for serious suspected cyanide poisoning, particularly after smoke inhalation, because it binds cyanide without deliberately reducing the blood’s oxygen-carrying capacity.

Cyanide Toxicity – Mechanism

Cyanide primarily inhibits mitochondrial cytochrome c oxidase (Complex IV).

This prevents cells from effectively using oxygen for oxidative phosphorylation.

The sequence is:

Cytochrome oxidase inhibition → failure of oxidative phosphorylation → ATP depletion → cellular hypoxia despite available oxygen

The result is rapid histotoxic hypoxia.

Consequences of Cellular Respiratory Failure

Severe cyanide poisoning can cause:

• Marked lactic acidosis
• Altered mental status
• Seizures
• Hypotension
• Dysrhythmias
• Cardiovascular collapse
• Coma
• Cardiac arrest

The brain and cardiovascular system are particularly vulnerable because of their high energy requirements.

Important Exposure Sources

Potential sources include:

• Enclosed-space structural fires
• Cyanide salts
• Hydrogen cyanide gas
• Certain industrial processes
• Some laboratory chemicals
• Selected occupational exposures
• Excessive/prolonged sodium nitroprusside exposure
• Certain cyanogenic compounds

Clinical context is essential because cyanide concentrations are often not rapidly available.

Smoke Inhalation

Cyanide should be considered in a severely ill patient following an enclosed-space fire, particularly with:

• Altered mental status
• Hypotension
• Cardiovascular collapse
• Severe metabolic/lactic acidosis
• Soot or evidence of significant smoke exposure

However, smoke inhalation can simultaneously cause:

• Carbon monoxide poisoning
• Cyanide poisoning
• Thermal airway injury
• Pulmonary irritant injury

Therefore, multiple mechanisms may coexist.

Lactate as a Clinical Clue

A markedly elevated lactate after a compatible exposure can support the diagnosis of severe cyanide poisoning.

However:

Elevated lactate is not specific for cyanide.

Other causes include:

• Shock
• Seizures
• Severe hypoxia
• Sepsis
• Stimulant toxicity
• Other mitochondrial poisons

The diagnosis remains clinical and exposure-based.

Do Not Wait for a Cyanide Level

Cyanide testing is generally too slow to guide emergency treatment.

In a patient with a strongly compatible exposure and severe clinical toxicity:

Antidotal treatment should not be delayed while waiting for laboratory confirmation.

Immediate Management

Priorities include:

• Remove the patient from ongoing exposure without endangering rescuers.
• Support airway and ventilation.
• Give high-concentration oxygen when indicated.
• Treat seizures.
• Support circulation.
• Correct immediately life-threatening metabolic abnormalities.
• Administer an appropriate cyanide antidote when clinically indicated.

Antidotes complement rather than replace aggressive supportive care.

Modern Preferred Antidote – Hydroxocobalamin

Hydroxocobalamin is a vitamin B12 precursor that directly binds cyanide.

The reaction produces:

Cyanide + hydroxocobalamin → cyanocobalamin

Cyanocobalamin is substantially less toxic and is eliminated from the body.

Advantages of Hydroxocobalamin

A major advantage is that it:

Does not intentionally produce methemoglobinemia.

This is especially important in smoke-inhalation victims who may already have impaired oxygen delivery from:

• Carbon monoxide
• Pulmonary injury
• Hypoxemia

Hydroxocobalamin is therefore particularly useful when cyanide poisoning and carbon monoxide exposure may coexist.

Hydroxocobalamin Adverse Effects

Important effects include:

• Transient hypertension
• Red discoloration of skin
• Dark red urine
• Interference with some laboratory assays

The intense red coloration can also interfere with certain optical monitoring or laboratory technologies.

These effects should not be mistaken for worsening cyanide toxicity.

Historical Nitrite–Thiosulfate Antidote System

The traditional cyanide kit relied on two complementary mechanisms:

Nitrites

Produce methemoglobin.

Sodium thiosulfate

Provides sulfur substrate that assists conversion of cyanide to thiocyanate.

This strategy can still have selected roles, but it is no longer the preferred default approach in many emergency settings.

Sodium Nitrite – Mechanism

Sodium nitrite oxidizes hemoglobin iron:

Fe²⁺ → Fe³⁺

This converts hemoglobin into methemoglobin.

Methemoglobin can bind cyanide, forming cyanomethemoglobin and reducing the amount of cyanide available to inhibit mitochondrial cytochrome oxidase.

Problem With Nitrite Therapy

Methemoglobin cannot transport oxygen normally.

Therefore:

The antidote itself decreases functional oxygen-carrying capacity.

Excessive methemoglobinemia can produce:

• Cyanosis
• Headache
• Dyspnea
• Tachycardia
• Altered mental status
• Tissue hypoxia
• Cardiovascular instability

This creates an important therapeutic limitation.

Why Nitrites Are Concerning in Smoke Inhalation

A smoke-inhalation victim may already have substantial carboxyhemoglobin from carbon monoxide.

Giving nitrite can add methemoglobin.

The combination produces:

Carboxyhemoglobin + methemoglobin → further reduction in functional oxygen-carrying capacity

For this reason, deliberate methemoglobin formation is generally undesirable when significant carbon monoxide poisoning may coexist.

Hydroxocobalamin has largely solved this problem.

Amyl Nitrite

Historically, amyl nitrite was inhaled as a temporary measure while IV access was being established.

Its purpose was to produce methemoglobin rapidly.

This approach is now largely obsolete.

Priorities such as:

• Effective oxygenation
• Ventilation
• Circulatory support
• Rapid definitive antidotal therapy

are more important than attempting to create methemoglobinemia using inhaled amyl nitrite.

Sodium Thiosulfate

Sodium thiosulfate acts differently from nitrites.

It provides a sulfur donor that facilitates enzymatic detoxification of cyanide into thiocyanate.

Thiocyanate is much less toxic than cyanide and is primarily eliminated through the kidneys.

Advantages of Sodium Thiosulfate

Unlike nitrites, sodium thiosulfate:

• Does not intentionally produce methemoglobinemia
• Does not directly impair hemoglobin oxygen transport

It may be used as an adjunct in selected cyanide poisonings.

However, its onset is slower than direct cyanide-binding therapy, making it less attractive as the sole antidote in rapidly deteriorating severe poisoning.

Renal Failure and Thiocyanate

Thiocyanate depends substantially on renal elimination.

Therefore, significant renal dysfunction can result in accumulation.

Excess thiocyanate may produce:

• Nausea
• Weakness
• Confusion
• Neurologic abnormalities
• Other systemic manifestations

Renal function becomes particularly important when thiosulfate-based therapy or prolonged nitroprusside exposure is involved.

Hydroxocobalamin + Sodium Thiosulfate

In selected severe cyanide poisoning, sodium thiosulfate may be considered alongside hydroxocobalamin.

However, antidotal combinations and administration should follow current toxicology/poison-center protocols.

The key concept is that the two drugs use different mechanisms:

Hydroxocobalamin binds cyanide directly.

Thiosulfate promotes conversion to thiocyanate.

Sodium Nitroprusside and Cyanide

Sodium nitroprusside metabolism can release cyanide.

Risk increases with:

• High infusion rates
• Prolonged exposure
• Limited detoxification capacity
• Severe illness

Potential manifestations include:

• Unexplained metabolic/lactic acidosis
• Altered mental status
• Cardiovascular instability
• Apparent resistance to expected nitroprusside effects

Management includes stopping the exposure and treating clinically significant cyanide toxicity appropriately.

Cyanide and Hyperkalemia

Severe cyanide poisoning can be associated with metabolic derangements, but hyperkalemia is not sufficiently specific to serve as a defining diagnostic feature.

The more characteristic laboratory clue in severe acute poisoning is:

Marked lactic acidosis in the appropriate exposure setting.

Hydrogen Sulfide – Important Modern Correction

The historical cyanide kit was also proposed for hydrogen sulfide (H₂S) poisoning, particularly sodium nitrite therapy.

The rationale was that induced methemoglobin might bind sulfide.

However, modern evidence does not support routine nitrite-induced methemoglobinemia as established therapy for hydrogen sulfide poisoning.

Modern Hydrogen Sulfide Management

Treatment primarily consists of:

• Immediate removal from exposure by appropriately protected rescuers
• High-concentration oxygen
• Airway and ventilatory support
• Cardiovascular resuscitation
• Seizure management
• General critical care

Because hydrogen sulfide can incapacitate rescuers extremely rapidly, protected rescue is essential.

Use of specific antidotal strategies remains less established than treatment of cyanide poisoning.

Cyanide vs Hydrogen Sulfide

Both can inhibit cellular respiration and produce:

• Rapid collapse
• Severe neurologic dysfunction
• Cardiovascular failure
• Lactic acidosis

But they are distinct poisons, and evidence for cyanide antidotes should not automatically be extrapolated to hydrogen sulfide.

Methemoglobin Monitoring

If a methemoglobin-forming antidote is used, monitor:

• Methemoglobin concentration by co-oximetry
• Oxygenation
• Hemoglobin concentration
• Hemodynamics
• Mental status
• Acid-base status

Pulse oximetry alone cannot accurately quantify methemoglobinemia.

Why Anemia Matters

A patient with anemia already has reduced oxygen-carrying capacity.

Converting part of the remaining hemoglobin into methemoglobin can further compromise oxygen delivery.

Therefore, deliberate methemoglobinemia is particularly concerning in:

• Significant anemia
• Carbon monoxide poisoning
• Preexisting methemoglobinemia
• Severe pulmonary injury
• Other states of impaired oxygen delivery

Pregnancy

Severe maternal cyanide poisoning poses an immediate threat to both mother and fetus.

Pregnancy should therefore not delay necessary antidotal treatment.

The obsolete FDA pregnancy-category framework should not determine emergency management.

Monitoring Severe Cyanide Poisoning

Monitor:

• Airway and ventilation
• Oxygenation
• Continuous ECG
• Blood pressure
• Mental status
• Temperature
• Blood gas
• Lactate
• Electrolytes
• Renal function

When relevant, also measure:

• Carboxyhemoglobin
• Methemoglobin

Serial clinical reassessment is more useful than waiting for cyanide concentrations.

Important Modernization of the Older Source

Several major updates are necessary:

• The traditional amyl nitrite + sodium nitrite + sodium thiosulfate cyanide kit is no longer the preferred default antidotal strategy.
• Hydroxocobalamin is generally preferred for serious suspected cyanide poisoning, particularly after smoke inhalation.
• Hydroxocobalamin binds cyanide without intentionally causing methemoglobinemia.
• Nitrite therapy can impair oxygen delivery and is particularly problematic when carbon monoxide poisoning, anemia, or existing methemoglobinemia is present.
• Amyl nitrite pearls have little role in contemporary emergency treatment.
• Sodium thiosulfate remains a potential adjunct but acts more slowly.
• Laboratory confirmation of cyanide exposure should not delay antidotal therapy in a critically ill patient with a compatible exposure.
• Marked lactate elevation is an important clue but is not specific for cyanide.
• Routine prophylactic antidote administration to an asymptomatic exposed person is not automatically appropriate.
• The historical recommendation for routine sodium nitrite treatment of hydrogen sulfide poisoning is not established modern practice.
• Current hydrogen sulfide treatment emphasizes rapid protected rescue and aggressive supportive care.
• Historical fixed antidote regimens should be replaced by current product-specific emergency and poison-center protocols.

Key Points

• Cyanide inhibits mitochondrial cytochrome c oxidase, preventing effective cellular oxygen utilization.
• Severe poisoning causes histotoxic hypoxia and profound lactic acidosis.
• Rapid neurologic and cardiovascular collapse can occur.
• Do not wait for a cyanide level when severe poisoning is clinically suspected.
• Hydroxocobalamin is generally the preferred modern antidote.
• Hydroxocobalamin directly binds cyanide to form cyanocobalamin.
• It does not intentionally decrease oxygen-carrying capacity.
• This makes it especially useful in smoke-inhalation victims who may also have carbon monoxide poisoning.
• Sodium nitrite works by creating methemoglobin, which can bind cyanide.
• Excess methemoglobin itself impairs oxygen transport.
• Nitrites therefore require particular caution when oxygen delivery is already compromised.
• Sodium thiosulfate promotes conversion of cyanide to thiocyanate.
• Thiocyanate is primarily renally eliminated and can accumulate in renal failure.
• Amyl nitrite is largely obsolete in modern cyanide management.
• Smoke inhalation may simultaneously produce cyanide toxicity, carbon monoxide poisoning, and pulmonary injury.
• Routine nitrite therapy for hydrogen sulfide poisoning is not supported by strong modern evidence.
• Antidotes never replace aggressive airway, ventilation, oxygenation, seizure, and circulatory support.

Toxicology – Cholestyramine

Core Concept

Cholestyramine is a nonabsorbable bile-acid sequestrant that binds bile acids and some medications or chemicals within the gastrointestinal tract.

Its established clinical use is primarily for conditions such as hypercholesterolemia and selected bile-acid disorders.

In toxicology, its role is limited and uncommon. It has been investigated as a way to increase gastrointestinal elimination of selected toxins, particularly compounds undergoing enterohepatic recirculation.

Mechanism of Action

Cholestyramine is an anion-exchange resin that remains within the gastrointestinal tract.

It:

• Binds bile acids in the intestine
• Forms poorly absorbed complexes
• Prevents bile-acid reabsorption
• Increases fecal elimination

Loss of bile acids causes the liver to convert additional cholesterol into bile acids, contributing to its lipid-lowering effect.

Toxicologic Mechanism

Some drugs and toxins are:

absorbed → metabolized or secreted into bile → returned to intestine → reabsorbed

This is called enterohepatic recirculation.

Cholestyramine may bind certain compounds after they enter the intestinal lumen and thereby:

Reduce reabsorption → increase fecal elimination

This is sometimes described as interruption of enterohepatic cycling.

Cholestyramine vs Activated Charcoal

These are different gastrointestinal binding agents.

Activated Charcoal

• Has a very large porous surface area
• Adsorbs many organic drugs and toxins
• Has a much broader toxicologic role
• Multiple-dose activated charcoal can enhance elimination of selected systemic poisons

Cholestyramine

• Primarily binds bile acids and selected compounds
• Has a much narrower toxicologic role
• Is not a general substitute for activated charcoal
• Has limited evidence for improving outcomes in acute poisoning

Organochlorine Pesticides

Cholestyramine has historically been investigated for organochlorine compounds because some undergo substantial enterohepatic circulation.

It may increase fecal elimination of selected compounds.

However:

Enhanced elimination does not necessarily translate into improved clinical outcomes.

Routine use for organochlorine pesticide poisoning is therefore not established.

Chlordecone

An important historical example is chlordecone (Kepone).

This highly persistent organochlorine compound undergoes substantial enterohepatic recycling.

Cholestyramine has been used to:

• Interrupt enterohepatic circulation
• Increase fecal elimination
• Reduce body burden during prolonged exposure

This is a specialized situation rather than evidence that cholestyramine should routinely be used for pesticide poisoning in general.

Cardiac Glycosides

Cholestyramine can bind some cardiac glycosides in the gastrointestinal tract and has historically been investigated for:

• Digoxin
• Digitoxin

It may increase their fecal elimination, particularly for compounds with enterohepatic recycling.

However, it is not the primary treatment for severe cardiac glycoside poisoning.

Severe Digoxin Toxicity

Potential manifestations include:

• Nausea and vomiting
• Confusion
• Visual abnormalities
• Bradycardia
• AV block
• Ventricular dysrhythmias
• Hyperkalemia in severe acute poisoning

For clinically important or life-threatening digoxin toxicity, the specific antidote is:

Digoxin immune Fab

Cholestyramine should not delay Fab when Fab is indicated.

Digitoxin

Digitoxin undergoes more extensive enterohepatic recirculation than digoxin.

Therefore, gastrointestinal binding strategies theoretically have a greater effect on digitoxin elimination.

Nevertheless, modern management of serious cardiac glycoside poisoning remains driven by:

• Clinical toxicity
• ECG abnormalities
• Electrolytes
• Appropriate use of digoxin immune Fab

rather than routine cholestyramine therapy.

Drug Binding and Interactions

Because cholestyramine remains in the gut and binds many compounds, it can reduce absorption of concurrently administered oral medications.

Potentially affected drugs include selected:

• Thyroid hormones
• Warfarin and other medications affected by vitamin K status
• Digoxin and digitoxin
• Diuretics
• Some antibiotics
• Antiepileptic medications
• Immunosuppressants
• Lipid-lowering medications

The interaction depends on the individual drug.

Important Toxicologic Interaction

A particularly important principle is:

Cholestyramine may bind an orally administered antidote or essential medication as well as the toxin.

Therefore, when cholestyramine is being considered, clinicians must determine whether it could interfere with other necessary oral therapy.

Fat-Soluble Vitamins

Chronic cholestyramine therapy can impair absorption of:

• Vitamin A
• Vitamin D
• Vitamin E
• Vitamin K

Vitamin K deficiency can lead to:

• Prolonged coagulation testing
• Reduced clotting-factor activity
• Increased bleeding tendency

This is primarily a concern with prolonged use rather than a brief toxicologic course.

Adverse Effects

Most adverse effects are gastrointestinal.

Common effects include:

• Constipation
• Abdominal discomfort
• Bloating
• Flatulence
• Nausea
• Indigestion

Other possible effects include:

• Vomiting
• Diarrhea
• Steatorrhea

Rarely, significant constipation can contribute to fecal impaction or intestinal obstruction.

Bowel Obstruction

Cholestyramine should not be used when gastrointestinal transit is severely impaired.

Important concerns include:

• Complete bowel obstruction
• Severe ileus
• Significant fecal impaction

A gastrointestinal binding treatment cannot provide useful elimination when bowel contents cannot progress normally.

Biliary Obstruction

Complete biliary obstruction is a contraindication to its conventional bile-acid-sequestrant use.

If bile cannot reach the intestine, the normal therapeutic mechanism of binding intestinal bile acids is largely irrelevant.

Pregnancy

The historical FDA pregnancy letter categories are obsolete.

Cholestyramine is not meaningfully systemically absorbed, so direct fetal exposure is expected to be minimal.

However, prolonged use can interfere with maternal absorption of:

• Fat-soluble vitamins
• Folate
• Certain medications

These nutritional and medication interactions are more relevant than systemic exposure to cholestyramine itself.

Breastfeeding

Because cholestyramine is not appreciably absorbed from the maternal gastrointestinal tract, direct transfer into breast milk is not expected to be significant.

The older statement that it should simply be avoided during breastfeeding is too broad.

With prolonged treatment, however, maternal vitamin absorption and nutritional status should be considered.

Role in Acute Poisoning

Cholestyramine has no broadly accepted routine role in most acute overdoses.

Reasons include:

• Limited range of toxins effectively bound
• Uncertain effect on clinically meaningful outcomes
• Gastrointestinal adverse effects
• Potential binding of necessary medications
• Availability of better-established antidotes and elimination techniques

Its use is therefore generally restricted to selected compounds or specialist-directed circumstances.

No Universal Toxicology Dose

There is no single established cholestyramine regimen for poisoning.

The conventional doses used for hypercholesterolemia should not automatically be extrapolated to overdose management.

When cholestyramine is considered for a specific toxic exposure, therapy should be based on evidence for that substance and specialist guidance.

Comparison With Multiple-Dose Activated Charcoal

Multiple-dose activated charcoal has a better-established role in enhancing elimination of selected toxins, classically:

• Carbamazepine
• Dapsone
• Phenobarbital
• Quinine
• Theophylline

Cholestyramine should not replace MDAC for these established indications merely because both agents can bind compounds in the intestine.

Comparison With Whole-Bowel Irrigation

Whole-bowel irrigation and cholestyramine also work differently.

Whole-bowel irrigation

Physically moves intestinal contents through the GI tract.

Cholestyramine

Chemically binds selected compounds within the intestine.

Whole-bowel irrigation may be considered in selected exposures such as:

• Certain sustained-release preparations
• Iron
• Lithium
• Drug packets

Cholestyramine does not serve the same purpose.

Monitoring

If cholestyramine is used in a toxicologic setting, monitor for:

• Constipation
• Abdominal distension
• Vomiting
• Bowel function
• Ability to tolerate oral therapy
• Interactions with essential medications

With prolonged use, also consider:

• Fat-soluble vitamin deficiency
• Coagulation abnormalities
• Nutritional effects

Important Modernization of the Older Source

Several points require clarification:

• Cholestyramine is not a standard general gastrointestinal decontamination agent.
• Its potential toxicologic benefit comes mainly from binding selected compounds and interrupting enterohepatic recirculation.
• Evidence that it improves outcomes in most acute poisonings remains limited.
• Routine use for organochlorine pesticide poisoning is not recommended simply on the basis of increased fecal elimination.
• Chlordecone is an important specialized example where interruption of enterohepatic recycling has been useful.
• Cholestyramine is not standard definitive therapy for digoxin toxicity; digoxin immune Fab is the key antidote for serious poisoning.
• The old FDA pregnancy Category C designation is obsolete.
• Breastfeeding is not automatically contraindicated because cholestyramine is minimally absorbed, although prolonged treatment can affect maternal nutrient absorption.
• Its ability to bind other oral medications can be clinically important.
• There is no established universal toxicologic dosing regimen.

Key Points

• Cholestyramine is a nonabsorbable bile-acid sequestrant.
• It binds substances within the intestinal lumen and promotes fecal elimination.
• It can interrupt enterohepatic recirculation of selected compounds.
• Its role in modern clinical toxicology is limited and specialized.
• Chlordecone is a classic example where cholestyramine has been used to enhance elimination.
• It has been investigated for digoxin and digitoxin elimination but is not first-line treatment for severe cardiac glycoside toxicity.
• Digoxin immune Fab remains the important antidote for serious digoxin poisoning.
• Cholestyramine is not a substitute for activated charcoal, multiple-dose activated charcoal, or whole-bowel irrigation.
• It can decrease absorption of many therapeutic medications.
• Chronic treatment can impair absorption of vitamins A, D, E, and K.
• Constipation and abdominal discomfort are common; obstruction is a rare but important complication.
• Because it is minimally absorbed, systemic toxicity is limited.
• There is no universally accepted poisoning dose or broad indication for routine use in acute overdose.

195. Toxicology – Cholestyramine

Core Concept

Cholestyramine is a nonabsorbable bile-acid sequestrant that binds bile acids and some medications or chemicals within the gastrointestinal tract.

Its established clinical use is primarily for conditions such as hypercholesterolemia and selected bile-acid disorders.

In toxicology, its role is limited and uncommon. It has been investigated as a way to increase gastrointestinal elimination of selected toxins, particularly compounds undergoing enterohepatic recirculation.

Mechanism of Action

Cholestyramine is an anion-exchange resin that remains within the gastrointestinal tract.

It:

• Binds bile acids in the intestine
• Forms poorly absorbed complexes
• Prevents bile-acid reabsorption
• Increases fecal elimination

Loss of bile acids causes the liver to convert additional cholesterol into bile acids, contributing to its lipid-lowering effect.

Toxicologic Mechanism

Some drugs and toxins are:

absorbed → metabolized or secreted into bile → returned to intestine → reabsorbed

This is called enterohepatic recirculation.

Cholestyramine may bind certain compounds after they enter the intestinal lumen and thereby:

Reduce reabsorption → increase fecal elimination

This is sometimes described as interruption of enterohepatic cycling.

Cholestyramine vs Activated Charcoal

These are different gastrointestinal binding agents.

Activated Charcoal

• Has a very large porous surface area
• Adsorbs many organic drugs and toxins
• Has a much broader toxicologic role
• Multiple-dose activated charcoal can enhance elimination of selected systemic poisons

Cholestyramine

• Primarily binds bile acids and selected compounds
• Has a much narrower toxicologic role
• Is not a general substitute for activated charcoal
• Has limited evidence for improving outcomes in acute poisoning

Organochlorine Pesticides

Cholestyramine has historically been investigated for organochlorine compounds because some undergo substantial enterohepatic circulation.

It may increase fecal elimination of selected compounds.

However:

Enhanced elimination does not necessarily translate into improved clinical outcomes.

Routine use for organochlorine pesticide poisoning is therefore not established.

Chlordecone

An important historical example is chlordecone (Kepone).

This highly persistent organochlorine compound undergoes substantial enterohepatic recycling.

Cholestyramine has been used to:

• Interrupt enterohepatic circulation
• Increase fecal elimination
• Reduce body burden during prolonged exposure

This is a specialized situation rather than evidence that cholestyramine should routinely be used for pesticide poisoning in general.

Cardiac Glycosides

Cholestyramine can bind some cardiac glycosides in the gastrointestinal tract and has historically been investigated for:

• Digoxin
• Digitoxin

It may increase their fecal elimination, particularly for compounds with enterohepatic recycling.

However, it is not the primary treatment for severe cardiac glycoside poisoning.

Severe Digoxin Toxicity

Potential manifestations include:

• Nausea and vomiting
• Confusion
• Visual abnormalities
• Bradycardia
• AV block
• Ventricular dysrhythmias
• Hyperkalemia in severe acute poisoning

For clinically important or life-threatening digoxin toxicity, the specific antidote is:

Digoxin immune Fab

Cholestyramine should not delay Fab when Fab is indicated.

Digitoxin

Digitoxin undergoes more extensive enterohepatic recirculation than digoxin.

Therefore, gastrointestinal binding strategies theoretically have a greater effect on digitoxin elimination.

Nevertheless, modern management of serious cardiac glycoside poisoning remains driven by:

• Clinical toxicity
• ECG abnormalities
• Electrolytes
• Appropriate use of digoxin immune Fab

rather than routine cholestyramine therapy.

Drug Binding and Interactions

Because cholestyramine remains in the gut and binds many compounds, it can reduce absorption of concurrently administered oral medications.

Potentially affected drugs include selected:

• Thyroid hormones
• Warfarin and other medications affected by vitamin K status
• Digoxin and digitoxin
• Diuretics
• Some antibiotics
• Antiepileptic medications
• Immunosuppressants
• Lipid-lowering medications

The interaction depends on the individual drug.

Important Toxicologic Interaction

A particularly important principle is:

Cholestyramine may bind an orally administered antidote or essential medication as well as the toxin.

Therefore, when cholestyramine is being considered, clinicians must determine whether it could interfere with other necessary oral therapy.

Fat-Soluble Vitamins

Chronic cholestyramine therapy can impair absorption of:

• Vitamin A
• Vitamin D
• Vitamin E
• Vitamin K

Vitamin K deficiency can lead to:

• Prolonged coagulation testing
• Reduced clotting-factor activity
• Increased bleeding tendency

This is primarily a concern with prolonged use rather than a brief toxicologic course.

Adverse Effects

Most adverse effects are gastrointestinal.

Common effects include:

• Constipation
• Abdominal discomfort
• Bloating
• Flatulence
• Nausea
• Indigestion

Other possible effects include:

• Vomiting
• Diarrhea
• Steatorrhea

Rarely, significant constipation can contribute to fecal impaction or intestinal obstruction.

Bowel Obstruction

Cholestyramine should not be used when gastrointestinal transit is severely impaired.

Important concerns include:

• Complete bowel obstruction
• Severe ileus
• Significant fecal impaction

A gastrointestinal binding treatment cannot provide useful elimination when bowel contents cannot progress normally.

Biliary Obstruction

Complete biliary obstruction is a contraindication to its conventional bile-acid-sequestrant use.

If bile cannot reach the intestine, the normal therapeutic mechanism of binding intestinal bile acids is largely irrelevant.

Pregnancy

The historical FDA pregnancy letter categories are obsolete.

Cholestyramine is not meaningfully systemically absorbed, so direct fetal exposure is expected to be minimal.

However, prolonged use can interfere with maternal absorption of:

• Fat-soluble vitamins
• Folate
• Certain medications

These nutritional and medication interactions are more relevant than systemic exposure to cholestyramine itself.

Breastfeeding

Because cholestyramine is not appreciably absorbed from the maternal gastrointestinal tract, direct transfer into breast milk is not expected to be significant.

The older statement that it should simply be avoided during breastfeeding is too broad.

With prolonged treatment, however, maternal vitamin absorption and nutritional status should be considered.

Role in Acute Poisoning

Cholestyramine has no broadly accepted routine role in most acute overdoses.

Reasons include:

• Limited range of toxins effectively bound
• Uncertain effect on clinically meaningful outcomes
• Gastrointestinal adverse effects
• Potential binding of necessary medications
• Availability of better-established antidotes and elimination techniques

Its use is therefore generally restricted to selected compounds or specialist-directed circumstances.

No Universal Toxicology Dose

There is no single established cholestyramine regimen for poisoning.

The conventional doses used for hypercholesterolemia should not automatically be extrapolated to overdose management.

When cholestyramine is considered for a specific toxic exposure, therapy should be based on evidence for that substance and specialist guidance.

Comparison With Multiple-Dose Activated Charcoal

Multiple-dose activated charcoal has a better-established role in enhancing elimination of selected toxins, classically:

• Carbamazepine
• Dapsone
• Phenobarbital
• Quinine
• Theophylline

Cholestyramine should not replace MDAC for these established indications merely because both agents can bind compounds in the intestine.

Comparison With Whole-Bowel Irrigation

Whole-bowel irrigation and cholestyramine also work differently.

Whole-bowel irrigation

Physically moves intestinal contents through the GI tract.

Cholestyramine

Chemically binds selected compounds within the intestine.

Whole-bowel irrigation may be considered in selected exposures such as:

• Certain sustained-release preparations
• Iron
• Lithium
• Drug packets

Cholestyramine does not serve the same purpose.

Monitoring

If cholestyramine is used in a toxicologic setting, monitor for:

• Constipation
• Abdominal distension
• Vomiting
• Bowel function
• Ability to tolerate oral therapy
• Interactions with essential medications

With prolonged use, also consider:

• Fat-soluble vitamin deficiency
• Coagulation abnormalities
• Nutritional effects

Important Modernization of the Older Source

Several points require clarification:

• Cholestyramine is not a standard general gastrointestinal decontamination agent.
• Its potential toxicologic benefit comes mainly from binding selected compounds and interrupting enterohepatic recirculation.
• Evidence that it improves outcomes in most acute poisonings remains limited.
• Routine use for organochlorine pesticide poisoning is not recommended simply on the basis of increased fecal elimination.
• Chlordecone is an important specialized example where interruption of enterohepatic recycling has been useful.
• Cholestyramine is not standard definitive therapy for digoxin toxicity; digoxin immune Fab is the key antidote for serious poisoning.
• The old FDA pregnancy Category C designation is obsolete.
• Breastfeeding is not automatically contraindicated because cholestyramine is minimally absorbed, although prolonged treatment can affect maternal nutrient absorption.
• Its ability to bind other oral medications can be clinically important.
• There is no established universal toxicologic dosing regimen.

Key Points

• Cholestyramine is a nonabsorbable bile-acid sequestrant.
• It binds substances within the intestinal lumen and promotes fecal elimination.
• It can interrupt enterohepatic recirculation of selected compounds.
• Its role in modern clinical toxicology is limited and specialized.
• Chlordecone is a classic example where cholestyramine has been used to enhance elimination.
• It has been investigated for digoxin and digitoxin elimination but is not first-line treatment for severe cardiac glycoside toxicity.
• Digoxin immune Fab remains the important antidote for serious digoxin poisoning.
• Cholestyramine is not a substitute for activated charcoal, multiple-dose activated charcoal, or whole-bowel irrigation.
• It can decrease absorption of many therapeutic medications.
• Chronic treatment can impair absorption of vitamins A, D, E, and K.
• Constipation and abdominal discomfort are common; obstruction is a rare but important complication.
• Because it is minimally absorbed, systemic toxicity is limited.
• There is no universally accepted poisoning dose or broad indication for routine use in acute overdose.

Toxicology – Calcium as an Antidotal Therapy

Core Concept

Calcium is an important supportive or antidotal treatment in several toxicologic emergencies.

Major indications include:

• Calcium channel blocker (CCB) poisoning
• Hyperkalemia with cardiac toxicity
• Hypermagnesemia
• Hydrofluoric acid and other fluoride poisoning
• Selected toxin-induced symptomatic hypocalcemia

Older sources also recommended calcium for black widow spider envenomation, but this is no longer considered a reliably effective first-line treatment.

Calcium Preparations

The two major intravenous preparations are:

Calcium Chloride

• Provides substantially more elemental calcium per equivalent volume than calcium gluconate.
• Useful when rapid calcium delivery is required.
• More irritating to peripheral tissues.
• Extravasation can cause severe local tissue injury.

Calcium Gluconate

• Contains less elemental calcium.
• Less irritating to peripheral veins and tissues.
• Often preferred when peripheral IV administration is necessary.
• Commonly used for topical/local treatment of hydrofluoric acid skin exposure.

The preparations are not interchangeable gram-for-gram because they contain different amounts of elemental calcium.

General Mechanisms

Calcium works differently depending on the poisoning.

Hyperkalemia

Stabilizes the cardiac membrane against the electrophysiologic effects of excess potassium.

Hypermagnesemia

Functionally antagonizes some of magnesium’s effects on cardiac and neuromuscular tissues.

Calcium Channel Blocker Poisoning

Raises extracellular calcium availability and may partially overcome impaired calcium entry.

Fluoride Poisoning

Binds fluoride and replaces calcium depleted by fluoride-mediated complex formation.

Calcium Channel Blocker Poisoning

CCB overdose can produce:

• Bradycardia
• Hypotension
• AV block
• Cardiogenic shock
• Vasodilatory shock
• Hyperglycemia
• Altered mental status
• Severe dysrhythmias

Calcium is an important early therapy for clinically significant cardiovascular toxicity.

How Calcium Helps in CCB Poisoning

CCBs reduce calcium entry through L-type calcium channels.

Increasing extracellular calcium can partially overcome this functional blockade and improve:

• Contractility
• Blood pressure
• AV nodal conduction

However, the response is often incomplete or temporary.

Therefore:

Calcium is important, but severe CCB poisoning usually requires more than calcium alone.

Other Treatment in Severe CCB Poisoning

Depending on the clinical pattern, management may also require:

• Hyperinsulinemic euglycemia therapy
• Vasopressors
• Careful fluid resuscitation
• Airway and ventilatory support
• Correction of metabolic abnormalities
• Selected adjunctive therapies
• Extracorporeal circulatory support in refractory shock

Treatment is guided by the mechanism of cardiovascular failure.

Monitoring During CCB Treatment

Monitor:

• Continuous ECG
• Heart rate
• Blood pressure
• Perfusion
• Mental status
• Blood glucose
• Electrolytes
• Acid-base status
• Ionized calcium

Large amounts of calcium may sometimes be required, making repeated measurement particularly important.

Hyperkalemia

Calcium is one of the most important emergency therapies when hyperkalemia produces significant cardiac membrane instability.

ECG abnormalities may include:

• Peaked T waves
• PR prolongation
• P-wave attenuation or loss
• QRS widening
• Bradyarrhythmias
• Sine-wave morphology
• Ventricular dysrhythmias

However, ECG changes do not always follow a predictable sequence.

Severe hyperkalemia may exist without classic ECG findings.

What Calcium Does in Hyperkalemia

Calcium:

Stabilizes the myocardium

but it does not meaningfully remove potassium from the body or lower serum potassium concentration.

Therefore calcium must be followed by therapies that:

• Shift potassium intracellularly
• Remove potassium from the body
• Correct the underlying cause

when clinically indicated.

Hyperkalemia Treatment Concept

Think of treatment as three separate goals:

1. Protect the heart

→ Calcium

2. Temporarily shift potassium into cells

→ Insulin/glucose and selected other therapies

3. Remove excess potassium

→ Renal elimination, gastrointestinal potassium binders in selected settings, or dialysis when necessary

Calcium addresses only the first goal.

Digoxin Toxicity and Calcium

Older teaching described calcium as absolutely contraindicated in digoxin toxicity because of concern for so-called “stone heart.”

Modern evidence does not support an absolute prohibition.

If a patient with suspected digoxin toxicity has life-threatening hyperkalemia, calcium is not considered absolutely contraindicated.

However, the definitive antidotal treatment for severe digoxin poisoning is:

Digoxin immune Fab

Management should therefore focus on Fab when clinically indicated rather than relying on calcium.

Hypermagnesemia

Severe magnesium toxicity can produce:

• Nausea
• Flushing
• Hypotension
• Loss of deep tendon reflexes
• Muscle weakness
• Bradycardia
• Conduction abnormalities
• Respiratory depression
• Paralysis
• Cardiac arrest

Calcium can temporarily antagonize magnesium’s effects at cardiac and neuromuscular tissues.

Calcium in Magnesium Toxicity

IV calcium may improve:

• Cardiovascular instability
• Neuromuscular weakness
• Significant conduction abnormalities

But:

Calcium does not remove magnesium from the body.

Definitive management may require:

• Discontinuation of magnesium exposure
• Supportive care
• IV fluids and renal elimination when appropriate
• Dialysis in severe toxicity with renal impairment or refractory manifestations

Hydrofluoric Acid

Hydrofluoric acid (HF) is particularly dangerous because fluoride ions penetrate deeply into tissues.

The fluoride ion binds:

• Calcium
• Magnesium

This can cause:

• Local cellular destruction
• Severe pain
• Hypocalcemia
• Hypomagnesemia
• Hyperkalemia
• QT abnormalities
• Ventricular dysrhythmias
• Cardiac arrest

Small-appearing burns can occasionally produce disproportionately severe toxicity.

Why Calcium Works in HF Exposure

Calcium serves two important functions:

Calcium + fluoride → less biologically active calcium-fluoride complex

and

Calcium replacement → corrects fluoride-induced calcium depletion

Therefore, calcium therapy targets both the toxic fluoride ion and its systemic electrolyte consequences.

HF Skin Exposure

Immediate management begins with:

Prompt, prolonged water irrigation and removal of contaminated clothing

After decontamination, calcium gluconate gel is commonly used for symptomatic dermal HF exposure.

Persistent severe pain can indicate ongoing fluoride activity and deeper tissue injury.

Persistent HF Burns

If pain or tissue toxicity persists despite initial topical treatment, more advanced calcium delivery techniques may occasionally be necessary.

These require specialist management because improperly performed injections or vascular procedures can cause serious complications.

Potential escalation strategies are therefore best handled with:

• Medical toxicology
• Poison-center consultation
• Burn specialists
• Hand/plastic surgery when appropriate

Why Calcium Chloride Is Avoided in Tissue Injection

Calcium chloride is highly irritating and can produce:

• Tissue necrosis
• Severe local injury
• Extravasation damage

Therefore, it should not be injected intradermally or subcutaneously for HF burns.

Calcium gluconate is the safer calcium salt for local tissue treatment.

Systemic HF Poisoning

Severe fluoride exposure may rapidly cause:

• Hypocalcemia
• Hypomagnesemia
• Hyperkalemia
• QT prolongation
• Ventricular dysrhythmias
• Shock
• Cardiac arrest

Aggressive electrolyte monitoring and correction are essential.

Because deterioration can be rapid, severe HF poisoning requires high-acuity monitoring.

ECG in Fluoride Poisoning

ECG abnormalities can provide an early clue to severe electrolyte disruption.

Possible findings include:

• QT prolongation from hypocalcemia
• Conduction abnormalities
• Ventricular ectopy
• Ventricular tachycardia
• Ventricular fibrillation

Continuous ECG monitoring is appropriate in significant systemic exposure.

Other Fluoride Compounds

Similar systemic toxicity may occur with:

• Sodium fluoride
• Ammonium bifluoride
• Other soluble fluoride salts

These can cause:

• Hypocalcemia
• Hypomagnesemia
• Hyperkalemia
• GI injury
• Dysrhythmias

Treatment centers on supportive care and aggressive correction of clinically significant electrolyte disturbances.

Ethylene Glycol

Ethylene glycol metabolism produces oxalic acid.

Oxalate binds calcium and forms calcium oxalate crystals.

This contributes to:

• Hypocalcemia
• Tissue deposition
• Acute kidney injury

However, calcium should not automatically be administered merely because laboratory hypocalcemia is present.

Calcium is generally reserved for clinically important manifestations such as:

• Tetany
• Seizures attributable to hypocalcemia
• Significant dysrhythmia
• Other symptomatic hypocalcemia

Excessive calcium administration could theoretically promote additional calcium oxalate deposition.

Phosphate Poisoning

Large phosphate exposure can lower serum calcium through calcium-phosphate complex formation.

Severe hypocalcemia may produce:

• Paresthesias
• Tetany
• Seizures
• QT prolongation
• Dysrhythmias

Symptomatic or dangerous hypocalcemia may require calcium, while the underlying phosphate disturbance must also be addressed.

Black Widow Spider Envenomation

The older source recommended IV calcium as a major treatment for black widow envenomation.

This recommendation is now considered outdated.

Although calcium was historically proposed to counter venom-mediated alterations in neurotransmitter release, clinical benefit has been inconsistent.

Modern treatment emphasizes:

• Analgesia
• Supportive care
• Treatment of muscle spasm when necessary
• Antivenom for selected severe cases

Calcium is not routinely considered first-line therapy for latrodectism.

Calcium Chloride vs Calcium Gluconate

A practical distinction:

Calcium Chloride

Advantages:

• More elemental calcium
• Rapid calcium delivery

Disadvantages:

• Greater tissue toxicity
• Severe injury if extravasated

Calcium Gluconate

Advantages:

• Less irritating
• Better suited to peripheral administration
• Appropriate for topical HF treatment

Disadvantage:

• Less elemental calcium for an equivalent amount of solution

Extravasation

Calcium extravasation can cause significant tissue injury, particularly with calcium chloride.

Possible complications include:

• Pain
• Swelling
• Inflammation
• Tissue necrosis
• Calcification

If extravasation occurs:

• Stop administration through the affected line.
• Assess the site promptly.
• Follow an appropriate extravasation-management protocol.

Hypercalcemia from Treatment

Aggressive calcium therapy can produce excessive serum calcium.

Possible manifestations include:

• Nausea
• Weakness
• Confusion
• Hypertension
• Bradycardia or dysrhythmias
• Other conduction abnormalities

This is why ionized calcium and ECG findings should be followed during substantial therapy.

Renal Failure

Calcium therapy requires additional caution in patients with renal impairment because they may have:

• Altered calcium/phosphate balance
• Hyperphosphatemia
• Reduced ability to handle electrolyte loads

Treatment should be individualized according to the toxicologic emergency and measured electrolytes.

Pregnancy

Calcium is a normal physiologic electrolyte and can be administered during pregnancy when clinically indicated.

Life-threatening maternal electrolyte or cardiovascular toxicity should be treated promptly.

Monitoring During Significant Calcium Therapy

Monitor:

• Continuous ECG
• Heart rate and rhythm
• Blood pressure
• Ionized calcium
• Potassium
• Magnesium
• Renal function
• Acid-base status when appropriate

For fluoride toxicity, serial electrolyte measurements may need to be particularly frequent because abnormalities can change rapidly.

Important Modernization of the Older Source

Several recommendations in the source require updating:

• Calcium remains an important treatment for CCB toxicity, cardiac effects of hyperkalemia, severe hypermagnesemia, and fluoride toxicity.
• Calcium does not lower serum potassium; it stabilizes the myocardium while other therapies shift or remove potassium.
• The historical absolute contraindication to calcium in digoxin toxicity is no longer supported.
• Digoxin immune Fab remains the specific treatment for severe digoxin poisoning.
• Calcium is not routinely first-line treatment for black widow envenomation.
• In ethylene glycol poisoning, isolated laboratory hypocalcemia does not automatically require calcium; clinically significant symptomatic hypocalcemia is more important.
• Calcium chloride is more tissue-toxic than calcium gluconate and requires particular attention to IV access.
• Advanced HF treatments such as local infiltration, regional perfusion, or intra-arterial calcium should be specialist-directed rather than performed from rigid historical protocols.
• Fixed calcium regimens are less useful than treatment guided by ECG response, hemodynamics, symptoms, and serial ionized calcium measurements.
• Severe CCB poisoning generally requires multimodal therapy rather than calcium alone.

Key Points

• Calcium is an important toxicologic therapy for CCB poisoning, hyperkalemic cardiac toxicity, hypermagnesemia, and fluoride poisoning.
• Calcium chloride contains substantially more elemental calcium than calcium gluconate.
• Calcium chloride causes greater tissue injury if extravasation occurs.
• Calcium gluconate is generally safer through peripheral veins and is used locally for HF skin exposure.
• In CCB poisoning, calcium may improve contractility, blood pressure, and conduction but is often only one component of treatment.
• In hyperkalemia, calcium protects the myocardium but does not lower potassium.
• The old “stone heart” concern does not make calcium absolutely contraindicated in digoxin-associated hyperkalemia.
• Digoxin immune Fab is the definitive antidotal therapy for severe digoxin toxicity.
• In hypermagnesemia, calcium antagonizes magnesium’s physiologic effects but does not eliminate magnesium.
• Fluoride binds calcium and magnesium and can cause rapidly fatal electrolyte abnormalities and ventricular dysrhythmias.
• HF skin exposure requires immediate decontamination; topical calcium gluconate is commonly used for symptomatic burns.
• Severe or persistent HF injury requires specialist toxicology/burn management.
• Calcium chloride should not be injected into tissues for HF burns.
• Calcium is no longer considered reliable first-line treatment for black widow envenomation.
• During substantial calcium therapy, follow ECG, hemodynamics, ionized calcium, potassium, magnesium, and renal function.

194. Toxicology – Calcium as an Antidotal Therapy

Core Concept

Calcium is an important supportive or antidotal treatment in several toxicologic emergencies.

Major indications include:

• Calcium channel blocker (CCB) poisoning
• Hyperkalemia with cardiac toxicity
• Hypermagnesemia
• Hydrofluoric acid and other fluoride poisoning
• Selected toxin-induced symptomatic hypocalcemia

Older sources also recommended calcium for black widow spider envenomation, but this is no longer considered a reliably effective first-line treatment.

Calcium Preparations

The two major intravenous preparations are:

Calcium Chloride

• Provides substantially more elemental calcium per equivalent volume than calcium gluconate.
• Useful when rapid calcium delivery is required.
• More irritating to peripheral tissues.
• Extravasation can cause severe local tissue injury.

Calcium Gluconate

• Contains less elemental calcium.
• Less irritating to peripheral veins and tissues.
• Often preferred when peripheral IV administration is necessary.
• Commonly used for topical/local treatment of hydrofluoric acid skin exposure.

The preparations are not interchangeable gram-for-gram because they contain different amounts of elemental calcium.

General Mechanisms

Calcium works differently depending on the poisoning.

Hyperkalemia

Stabilizes the cardiac membrane against the electrophysiologic effects of excess potassium.

Hypermagnesemia

Functionally antagonizes some of magnesium’s effects on cardiac and neuromuscular tissues.

Calcium Channel Blocker Poisoning

Raises extracellular calcium availability and may partially overcome impaired calcium entry.

Fluoride Poisoning

Binds fluoride and replaces calcium depleted by fluoride-mediated complex formation.

Calcium Channel Blocker Poisoning

CCB overdose can produce:

• Bradycardia
• Hypotension
• AV block
• Cardiogenic shock
• Vasodilatory shock
• Hyperglycemia
• Altered mental status
• Severe dysrhythmias

Calcium is an important early therapy for clinically significant cardiovascular toxicity.

How Calcium Helps in CCB Poisoning

CCBs reduce calcium entry through L-type calcium channels.

Increasing extracellular calcium can partially overcome this functional blockade and improve:

• Contractility
• Blood pressure
• AV nodal conduction

However, the response is often incomplete or temporary.

Therefore:

Calcium is important, but severe CCB poisoning usually requires more than calcium alone.

Other Treatment in Severe CCB Poisoning

Depending on the clinical pattern, management may also require:

• Hyperinsulinemic euglycemia therapy
• Vasopressors
• Careful fluid resuscitation
• Airway and ventilatory support
• Correction of metabolic abnormalities
• Selected adjunctive therapies
• Extracorporeal circulatory support in refractory shock

Treatment is guided by the mechanism of cardiovascular failure.

Monitoring During CCB Treatment

Monitor:

• Continuous ECG
• Heart rate
• Blood pressure
• Perfusion
• Mental status
• Blood glucose
• Electrolytes
• Acid-base status
• Ionized calcium

Large amounts of calcium may sometimes be required, making repeated measurement particularly important.

Hyperkalemia

Calcium is one of the most important emergency therapies when hyperkalemia produces significant cardiac membrane instability.

ECG abnormalities may include:

• Peaked T waves
• PR prolongation
• P-wave attenuation or loss
• QRS widening
• Bradyarrhythmias
• Sine-wave morphology
• Ventricular dysrhythmias

However, ECG changes do not always follow a predictable sequence.

Severe hyperkalemia may exist without classic ECG findings.

What Calcium Does in Hyperkalemia

Calcium:

Stabilizes the myocardium

but it does not meaningfully remove potassium from the body or lower serum potassium concentration.

Therefore calcium must be followed by therapies that:

• Shift potassium intracellularly
• Remove potassium from the body
• Correct the underlying cause

when clinically indicated.

Hyperkalemia Treatment Concept

Think of treatment as three separate goals:

1. Protect the heart

→ Calcium

2. Temporarily shift potassium into cells

→ Insulin/glucose and selected other therapies

3. Remove excess potassium

→ Renal elimination, gastrointestinal potassium binders in selected settings, or dialysis when necessary

Calcium addresses only the first goal.

Digoxin Toxicity and Calcium

Older teaching described calcium as absolutely contraindicated in digoxin toxicity because of concern for so-called “stone heart.”

Modern evidence does not support an absolute prohibition.

If a patient with suspected digoxin toxicity has life-threatening hyperkalemia, calcium is not considered absolutely contraindicated.

However, the definitive antidotal treatment for severe digoxin poisoning is:

Digoxin immune Fab

Management should therefore focus on Fab when clinically indicated rather than relying on calcium.

Hypermagnesemia

Severe magnesium toxicity can produce:

• Nausea
• Flushing
• Hypotension
• Loss of deep tendon reflexes
• Muscle weakness
• Bradycardia
• Conduction abnormalities
• Respiratory depression
• Paralysis
• Cardiac arrest

Calcium can temporarily antagonize magnesium’s effects at cardiac and neuromuscular tissues.

Calcium in Magnesium Toxicity

IV calcium may improve:

• Cardiovascular instability
• Neuromuscular weakness
• Significant conduction abnormalities

But:

Calcium does not remove magnesium from the body.

Definitive management may require:

• Discontinuation of magnesium exposure
• Supportive care
• IV fluids and renal elimination when appropriate
• Dialysis in severe toxicity with renal impairment or refractory manifestations

Hydrofluoric Acid

Hydrofluoric acid (HF) is particularly dangerous because fluoride ions penetrate deeply into tissues.

The fluoride ion binds:

• Calcium
• Magnesium

This can cause:

• Local cellular destruction
• Severe pain
• Hypocalcemia
• Hypomagnesemia
• Hyperkalemia
• QT abnormalities
• Ventricular dysrhythmias
• Cardiac arrest

Small-appearing burns can occasionally produce disproportionately severe toxicity.

Why Calcium Works in HF Exposure

Calcium serves two important functions:

Calcium + fluoride → less biologically active calcium-fluoride complex

and

Calcium replacement → corrects fluoride-induced calcium depletion

Therefore, calcium therapy targets both the toxic fluoride ion and its systemic electrolyte consequences.

HF Skin Exposure

Immediate management begins with:

Prompt, prolonged water irrigation and removal of contaminated clothing

After decontamination, calcium gluconate gel is commonly used for symptomatic dermal HF exposure.

Persistent severe pain can indicate ongoing fluoride activity and deeper tissue injury.

Persistent HF Burns

If pain or tissue toxicity persists despite initial topical treatment, more advanced calcium delivery techniques may occasionally be necessary.

These require specialist management because improperly performed injections or vascular procedures can cause serious complications.

Potential escalation strategies are therefore best handled with:

• Medical toxicology
• Poison-center consultation
• Burn specialists
• Hand/plastic surgery when appropriate

Why Calcium Chloride Is Avoided in Tissue Injection

Calcium chloride is highly irritating and can produce:

• Tissue necrosis
• Severe local injury
• Extravasation damage

Therefore, it should not be injected intradermally or subcutaneously for HF burns.

Calcium gluconate is the safer calcium salt for local tissue treatment.

Systemic HF Poisoning

Severe fluoride exposure may rapidly cause:

• Hypocalcemia
• Hypomagnesemia
• Hyperkalemia
• QT prolongation
• Ventricular dysrhythmias
• Shock
• Cardiac arrest

Aggressive electrolyte monitoring and correction are essential.

Because deterioration can be rapid, severe HF poisoning requires high-acuity monitoring.

ECG in Fluoride Poisoning

ECG abnormalities can provide an early clue to severe electrolyte disruption.

Possible findings include:

• QT prolongation from hypocalcemia
• Conduction abnormalities
• Ventricular ectopy
• Ventricular tachycardia
• Ventricular fibrillation

Continuous ECG monitoring is appropriate in significant systemic exposure.

Other Fluoride Compounds

Similar systemic toxicity may occur with:

• Sodium fluoride
• Ammonium bifluoride
• Other soluble fluoride salts

These can cause:

• Hypocalcemia
• Hypomagnesemia
• Hyperkalemia
• GI injury
• Dysrhythmias

Treatment centers on supportive care and aggressive correction of clinically significant electrolyte disturbances.

Ethylene Glycol

Ethylene glycol metabolism produces oxalic acid.

Oxalate binds calcium and forms calcium oxalate crystals.

This contributes to:

• Hypocalcemia
• Tissue deposition
• Acute kidney injury

However, calcium should not automatically be administered merely because laboratory hypocalcemia is present.

Calcium is generally reserved for clinically important manifestations such as:

• Tetany
• Seizures attributable to hypocalcemia
• Significant dysrhythmia
• Other symptomatic hypocalcemia

Excessive calcium administration could theoretically promote additional calcium oxalate deposition.

Phosphate Poisoning

Large phosphate exposure can lower serum calcium through calcium-phosphate complex formation.

Severe hypocalcemia may produce:

• Paresthesias
• Tetany
• Seizures
• QT prolongation
• Dysrhythmias

Symptomatic or dangerous hypocalcemia may require calcium, while the underlying phosphate disturbance must also be addressed.

Black Widow Spider Envenomation

The older source recommended IV calcium as a major treatment for black widow envenomation.

This recommendation is now considered outdated.

Although calcium was historically proposed to counter venom-mediated alterations in neurotransmitter release, clinical benefit has been inconsistent.

Modern treatment emphasizes:

• Analgesia
• Supportive care
• Treatment of muscle spasm when necessary
• Antivenom for selected severe cases

Calcium is not routinely considered first-line therapy for latrodectism.

Calcium Chloride vs Calcium Gluconate

A practical distinction:

Calcium Chloride

Advantages:

• More elemental calcium
• Rapid calcium delivery

Disadvantages:

• Greater tissue toxicity
• Severe injury if extravasated

Calcium Gluconate

Advantages:

• Less irritating
• Better suited to peripheral administration
• Appropriate for topical HF treatment

Disadvantage:

• Less elemental calcium for an equivalent amount of solution

Extravasation

Calcium extravasation can cause significant tissue injury, particularly with calcium chloride.

Possible complications include:

• Pain
• Swelling
• Inflammation
• Tissue necrosis
• Calcification

If extravasation occurs:

• Stop administration through the affected line.
• Assess the site promptly.
• Follow an appropriate extravasation-management protocol.

Hypercalcemia from Treatment

Aggressive calcium therapy can produce excessive serum calcium.

Possible manifestations include:

• Nausea
• Weakness
• Confusion
• Hypertension
• Bradycardia or dysrhythmias
• Other conduction abnormalities

This is why ionized calcium and ECG findings should be followed during substantial therapy.

Renal Failure

Calcium therapy requires additional caution in patients with renal impairment because they may have:

• Altered calcium/phosphate balance
• Hyperphosphatemia
• Reduced ability to handle electrolyte loads

Treatment should be individualized according to the toxicologic emergency and measured electrolytes.

Pregnancy

Calcium is a normal physiologic electrolyte and can be administered during pregnancy when clinically indicated.

Life-threatening maternal electrolyte or cardiovascular toxicity should be treated promptly.

Monitoring During Significant Calcium Therapy

Monitor:

• Continuous ECG
• Heart rate and rhythm
• Blood pressure
• Ionized calcium
• Potassium
• Magnesium
• Renal function
• Acid-base status when appropriate

For fluoride toxicity, serial electrolyte measurements may need to be particularly frequent because abnormalities can change rapidly.

Important Modernization of the Older Source

Several recommendations in the source require updating:

• Calcium remains an important treatment for CCB toxicity, cardiac effects of hyperkalemia, severe hypermagnesemia, and fluoride toxicity.
• Calcium does not lower serum potassium; it stabilizes the myocardium while other therapies shift or remove potassium.
• The historical absolute contraindication to calcium in digoxin toxicity is no longer supported.
• Digoxin immune Fab remains the specific treatment for severe digoxin poisoning.
• Calcium is not routinely first-line treatment for black widow envenomation.
• In ethylene glycol poisoning, isolated laboratory hypocalcemia does not automatically require calcium; clinically significant symptomatic hypocalcemia is more important.
• Calcium chloride is more tissue-toxic than calcium gluconate and requires particular attention to IV access.
• Advanced HF treatments such as local infiltration, regional perfusion, or intra-arterial calcium should be specialist-directed rather than performed from rigid historical protocols.
• Fixed calcium regimens are less useful than treatment guided by ECG response, hemodynamics, symptoms, and serial ionized calcium measurements.
• Severe CCB poisoning generally requires multimodal therapy rather than calcium alone.

Key Points

• Calcium is an important toxicologic therapy for CCB poisoning, hyperkalemic cardiac toxicity, hypermagnesemia, and fluoride poisoning.
• Calcium chloride contains substantially more elemental calcium than calcium gluconate.
• Calcium chloride causes greater tissue injury if extravasation occurs.
• Calcium gluconate is generally safer through peripheral veins and is used locally for HF skin exposure.
• In CCB poisoning, calcium may improve contractility, blood pressure, and conduction but is often only one component of treatment.
• In hyperkalemia, calcium protects the myocardium but does not lower potassium.
• The old “stone heart” concern does not make calcium absolutely contraindicated in digoxin-associated hyperkalemia.
• Digoxin immune Fab is the definitive antidotal therapy for severe digoxin toxicity.
• In hypermagnesemia, calcium antagonizes magnesium’s physiologic effects but does not eliminate magnesium.
• Fluoride binds calcium and magnesium and can cause rapidly fatal electrolyte abnormalities and ventricular dysrhythmias.
• HF skin exposure requires immediate decontamination; topical calcium gluconate is commonly used for symptomatic burns.
• Severe or persistent HF injury requires specialist toxicology/burn management.
• Calcium chloride should not be injected into tissues for HF burns.
• Calcium is no longer considered reliable first-line treatment for black widow envenomation.
• During substantial calcium therapy, follow ECG, hemodynamics, ionized calcium, potassium, magnesium, and renal function.

Toxicology – Dimercaprol (British Anti-Lewisite, BAL)

Core Concept

Dimercaprol, historically called British Anti-Lewisite (BAL), is a parenteral heavy-metal chelator.

Its modern role is relatively limited because other chelators, particularly succimer (DMSA) and DMPS where available, are often easier to administer and better tolerated.

BAL remains important in selected severe poisonings, especially:

• Severe acute arsenic poisoning when oral therapy is unsuitable
• Lead encephalopathy, traditionally in combination with calcium disodium EDTA
• Selected severe inorganic mercury exposures when alternative chelators cannot be used
• Lewisite exposure in specialized settings

Chemical Properties

Dimercaprol contains two sulfhydryl (-SH) groups, making it a dithiol chelating agent.

It is:

• Lipid soluble
• Poorly water soluble
• Administered by deep intramuscular injection
• Traditionally formulated in an oil vehicle

Its unpleasant sulfur-like odor reflects its sulfhydryl chemistry.

Mechanism of Action

Many toxic metals bind sulfhydryl groups on enzymes and other cellular proteins.

Dimercaprol provides alternative sulfhydryl binding sites.

The general process is:

Toxic metal + BAL → metal–BAL complex → reduced interaction with critical cellular proteins → enhanced elimination

Chelation is most useful when the metal remains biologically accessible.

Historical Origin

BAL was originally developed during World War II as an antidote to Lewisite, an arsenic-containing chemical warfare vesicant.

The name therefore means:

British Anti-Lewisite

Its ability to bind arsenic subsequently led to use against other heavy metals.

Major Modern Limitation

BAL is not a general-purpose treatment for every elevated metal concentration.

Chelation decisions depend on:

• Specific metal
• Chemical form
• Exposure severity
• Symptoms
• Blood or urine concentrations when clinically meaningful
• Timing
• Renal function
• Availability of safer chelators

Chelation can itself cause toxicity and should generally involve a medical toxicologist or poison center.

Acute Arsenic Poisoning

Dimercaprol has an established historical role in severe acute inorganic arsenic poisoning.

Clinical manifestations may include:

• Severe vomiting and diarrhea
• Abdominal pain
• Hypotension
• QT abnormalities
• Dysrhythmias
• Encephalopathy
• Peripheral neuropathy
• Multiorgan dysfunction

Chelation should be considered early in severe symptomatic poisoning rather than waiting for delayed laboratory confirmation when the exposure is strongly supported.

BAL vs Oral Chelators in Arsenic Poisoning

For many patients, modern oral chelators such as:

• Succimer (DMSA)
• DMPS, where available

are preferred because they are generally easier to administer and better tolerated.

BAL is particularly useful when:

• Poisoning is severe
• The patient cannot tolerate oral medication
• Gastrointestinal toxicity prevents reliable absorption
• A parenteral chelator is considered necessary

Once oral treatment becomes appropriate, prolonged BAL therapy is usually unnecessary.

Arsine Gas

Arsine poisoning is fundamentally different from ingestion of inorganic arsenic.

Arsine primarily causes:

• Massive intravascular hemolysis
• Hemoglobinuria
• Acute kidney injury
• Anemia

Chelation has not been clearly demonstrated to provide the same benefit in arsine poisoning.

Management focuses heavily on:

• Supportive care
• Management of hemolysis
• Renal support
• Extracorporeal therapy when indicated

Lead Poisoning

BAL’s most important traditional lead indication is severe lead poisoning with encephalopathy.

Lead encephalopathy may present with:

• Altered mental status
• Severe headache
• Vomiting
• Ataxia
• Seizures
• Cerebral edema
• Coma

This is a medical emergency.

BAL and Calcium Disodium EDTA

Historically, severe lead encephalopathy has been treated with:

Dimercaprol + calcium disodium EDTA (CaNa₂EDTA)

BAL is started before or alongside CaNa₂EDTA according to specialist protocols.

The rationale is to reduce concerns about redistribution of mobilized lead and provide complementary chelation.

Exact regimens should follow current toxicology guidance rather than older fixed schedules.

Critical EDTA Distinction

Do not confuse:

Calcium disodium EDTA

CaNa₂EDTA – a lead chelator.

with:

Disodium EDTA

Na₂EDTA – can produce profound hypocalcemia and has caused fatal medication errors.

This distinction is clinically crucial.

Lead Poisoning Without Encephalopathy

BAL is generally not preferred for routine treatment of elevated blood lead concentrations without encephalopathy.

Depending on severity, alternatives may include:

• Succimer
• CaNa₂EDTA
• Other specialist-directed strategies

Removal from the lead source remains essential.

Mercury Poisoning

BAL has historically been used for selected severe inorganic mercury poisoning when oral chelators cannot be administered.

Modern alternatives commonly include:

• Succimer
• DMPS where available

The effectiveness of chelation depends strongly on the chemical form of mercury.

Elemental Mercury

Swallowed elemental mercury is poorly absorbed from an intact gastrointestinal tract.

Therefore, simple ingestion usually does not require BAL.

In contrast:

Inhaled mercury vapor → substantial systemic absorption

and may produce:

• Cough
• Dyspnea
• Pneumonitis
• Tremor
• Neuropsychiatric abnormalities
• Renal injury

Chelation decisions are individualized.

Organic Mercury

BAL should not be routinely used for methylmercury poisoning.

Historically, there has been concern that BAL may increase redistribution of mercury toward the CNS.

Modern management of significant organic mercury poisoning generally favors other chelators when chelation is indicated.

Gold Toxicity

BAL was historically used for toxicity caused by therapeutic gold compounds.

Gold therapy could produce:

• Bone-marrow toxicity
• Dermatitis
• Renal injury
• Other systemic adverse effects

Because therapeutic gold compounds are now rarely used, this indication has become uncommon.

Other Metals

BAL has historically been proposed for poisoning involving metals such as:

• Antimony
• Bismuth
• Copper
• Nickel
• Chromium

However, evidence and preferred chelation strategies differ substantially between metals.

BAL should therefore not be assumed to be appropriate simply because an exposure involves a metal.

BAL Must NOT Be Used for Iron Poisoning

This is a major high-yield contraindication.

BAL can form a potentially toxic complex with iron.

Therefore:

Iron poisoning → do not use dimercaprol.

The specific chelator for clinically important systemic iron poisoning is deferoxamine.

Cadmium

BAL should also not be used for cadmium poisoning.

Chelation can potentially increase renal delivery of cadmium and worsen nephrotoxicity.

Management of cadmium toxicity is primarily supportive and exposure-directed.

Selenium

Dimercaprol is also not a routine treatment for selenium poisoning.

Chelation recommendations must always be metal-specific.

Peanut-Oil Formulation

Traditional BAL preparations are formulated in peanut oil.

This historically raised concern regarding use in patients with peanut allergy.

The exact excipients of the available product should be checked because formulations can vary.

For severe life-threatening poisoning, specialist assessment of the actual risk and available alternatives is appropriate rather than treating every historical formulation warning as absolute.

G6PD Deficiency

Dimercaprol may increase the risk of hemolysis in patients with glucose-6-phosphate dehydrogenase deficiency.

This is especially relevant when repeated treatment is contemplated.

The risk must be balanced against the danger of severe metal poisoning.

Renal Function

Metal–chelator complexes often depend partly on renal elimination.

Renal impairment can therefore complicate chelation by allowing:

• Metal accumulation
• Chelator accumulation
• Persistence of metal–chelator complexes

Renal function and urine output should be followed during significant treatment.

Hepatic Disease

Because BAL itself can cause adverse effects and undergoes metabolism, significant hepatic dysfunction requires additional caution.

However, life-threatening metal poisoning may still justify treatment after specialist assessment.

Adverse Effects

BAL is relatively unpleasant compared with newer chelators.

Common adverse effects include:

• Painful IM injections
• Nausea
• Vomiting
• Headache
• Burning sensations
• Paresthesias
• Anxiety or restlessness
• Lacrimation
• Salivation
• Rhinorrhea
• Sweating
• Abdominal discomfort

Symptoms often become more prominent with greater exposure.

Cardiovascular Effects

Dimercaprol may cause:

• Tachycardia
• Hypertension

These effects can be more concerning in patients who already have:

• Severe hypertension
• Cardiovascular disease
• Significant autonomic instability

Monitoring is appropriate during treatment of severe poisoning.

Injection-Site Complications

Because BAL is administered as an oily intramuscular preparation, treatment may cause:

• Significant injection pain
• Local inflammation
• Sterile abscess formation

This is another reason oral chelators are preferred when clinically appropriate.

Essential Metal Loss

Chelators are not perfectly selective.

BAL can increase elimination of physiologically important metals such as:

• Copper
• Zinc

This is more relevant with prolonged treatment.

Pregnancy

The older FDA pregnancy letter categories and older animal-data framing should not be used in isolation.

Chelation during pregnancy requires consideration of:

• Metal involved
• Maternal toxicity
• Fetal toxicity from the metal itself
• Severity and timing of exposure
• Available alternative chelators

In severe life-threatening poisoning, necessary maternal treatment should not be withheld solely because of pregnancy.

Monitoring During BAL Therapy

Important monitoring may include:

• Clinical neurologic status
• Heart rate and blood pressure
• Renal function
• Urine output
• Liver function when appropriate
• CBC
• Evidence of hemolysis
• Relevant blood or urine metal concentrations
• Injection sites

Laboratory concentrations should always be interpreted in the context of the specific metal and timing of chelation.

Transition to Oral Chelation

A common principle is:

Use parenteral BAL during the severe phase when necessary → transition to a better-tolerated oral chelator once clinically appropriate.

Prolonging BAL after the patient can safely receive an effective alternative generally adds toxicity without clear benefit.

Chelation Does Not Replace Supportive Care

Even when BAL is indicated, management may still require treatment of:

• Shock
• Dysrhythmias
• Seizures
• Electrolyte disturbances
• Hemolysis
• Acute kidney injury
• Encephalopathy

Chelation is only one component of management.

Important Modernization of the Older Source

Several older recommendations require qualification:

• BAL now has a narrower role because succimer and DMPS are often better tolerated.
• It remains particularly relevant for severe acute arsenic poisoning when oral treatment is unsuitable and for traditional management of lead encephalopathy with CaNa₂EDTA.
• BAL is not recommended for routine treatment of elevated lead levels without encephalopathy.
• It should not be routinely used for methylmercury.
• BAL should be avoided in iron poisoning.
• BAL should be avoided in cadmium poisoning.
• The exact available formulation should be checked rather than assuming every product contains identical excipients.
• Historical fixed-duration and concentration-based chelation schedules should not replace individualized toxicology guidance.
• Hemodialysis is not simply a routine method for removing BAL–metal complexes; extracorporeal therapy depends on the specific metal, clinical syndrome, and renal failure.
• Chelation decisions should be based on the specific metal and its chemical form, not merely on the presence of “heavy-metal exposure.”

Key Points

• Dimercaprol = BAL = British Anti-Lewisite.
• It is a lipid-soluble dithiol chelator administered intramuscularly.
• Its sulfhydryl groups bind selected toxic metals.
• BAL was originally developed against the arsenical warfare agent Lewisite.
• Important modern uses include selected severe acute arsenic poisoning and lead encephalopathy.
• Severe lead encephalopathy has traditionally been treated with BAL plus calcium disodium EDTA.
• Never confuse CaNa₂EDTA with disodium EDTA.
• Succimer or DMPS is often preferred when an effective oral chelator can be used.
• BAL is generally not appropriate for chronic methylmercury toxicity.
• Do not use BAL for iron poisoning.
• Do not use BAL for cadmium poisoning.
• Important adverse effects include painful injections, nausea, autonomic symptoms, tachycardia, and hypertension.
• G6PD deficiency may increase the risk of hemolysis.
• Renal function is important because metal–chelator complexes must be eliminated.
• BAL should generally be replaced by a better-tolerated effective oral chelator once the clinical situation permits.
• Chelation should be directed by the specific metal, chemical form, severity, symptoms, and appropriate toxicologic testing rather than by a generic diagnosis of heavy-metal exposure.

193. Toxicology – Dimercaprol (British Anti-Lewisite, BAL)

Core Concept

Dimercaprol, historically called British Anti-Lewisite (BAL), is a parenteral heavy-metal chelator.

Its modern role is relatively limited because other chelators, particularly succimer (DMSA) and DMPS where available, are often easier to administer and better tolerated.

BAL remains important in selected severe poisonings, especially:

• Severe acute arsenic poisoning when oral therapy is unsuitable
• Lead encephalopathy, traditionally in combination with calcium disodium EDTA
• Selected severe inorganic mercury exposures when alternative chelators cannot be used
• Lewisite exposure in specialized settings

Chemical Properties

Dimercaprol contains two sulfhydryl (-SH) groups, making it a dithiol chelating agent.

It is:

• Lipid soluble
• Poorly water soluble
• Administered by deep intramuscular injection
• Traditionally formulated in an oil vehicle

Its unpleasant sulfur-like odor reflects its sulfhydryl chemistry.

Mechanism of Action

Many toxic metals bind sulfhydryl groups on enzymes and other cellular proteins.

Dimercaprol provides alternative sulfhydryl binding sites.

The general process is:

Toxic metal + BAL → metal–BAL complex → reduced interaction with critical cellular proteins → enhanced elimination

Chelation is most useful when the metal remains biologically accessible.

Historical Origin

BAL was originally developed during World War II as an antidote to Lewisite, an arsenic-containing chemical warfare vesicant.

The name therefore means:

British Anti-Lewisite

Its ability to bind arsenic subsequently led to use against other heavy metals.

Major Modern Limitation

BAL is not a general-purpose treatment for every elevated metal concentration.

Chelation decisions depend on:

• Specific metal
• Chemical form
• Exposure severity
• Symptoms
• Blood or urine concentrations when clinically meaningful
• Timing
• Renal function
• Availability of safer chelators

Chelation can itself cause toxicity and should generally involve a medical toxicologist or poison center.

Acute Arsenic Poisoning

Dimercaprol has an established historical role in severe acute inorganic arsenic poisoning.

Clinical manifestations may include:

• Severe vomiting and diarrhea
• Abdominal pain
• Hypotension
• QT abnormalities
• Dysrhythmias
• Encephalopathy
• Peripheral neuropathy
• Multiorgan dysfunction

Chelation should be considered early in severe symptomatic poisoning rather than waiting for delayed laboratory confirmation when the exposure is strongly supported.

BAL vs Oral Chelators in Arsenic Poisoning

For many patients, modern oral chelators such as:

• Succimer (DMSA)
• DMPS, where available

are preferred because they are generally easier to administer and better tolerated.

BAL is particularly useful when:

• Poisoning is severe
• The patient cannot tolerate oral medication
• Gastrointestinal toxicity prevents reliable absorption
• A parenteral chelator is considered necessary

Once oral treatment becomes appropriate, prolonged BAL therapy is usually unnecessary.

Arsine Gas

Arsine poisoning is fundamentally different from ingestion of inorganic arsenic.

Arsine primarily causes:

• Massive intravascular hemolysis
• Hemoglobinuria
• Acute kidney injury
• Anemia

Chelation has not been clearly demonstrated to provide the same benefit in arsine poisoning.

Management focuses heavily on:

• Supportive care
• Management of hemolysis
• Renal support
• Extracorporeal therapy when indicated

Lead Poisoning

BAL’s most important traditional lead indication is severe lead poisoning with encephalopathy.

Lead encephalopathy may present with:

• Altered mental status
• Severe headache
• Vomiting
• Ataxia
• Seizures
• Cerebral edema
• Coma

This is a medical emergency.

BAL and Calcium Disodium EDTA

Historically, severe lead encephalopathy has been treated with:

Dimercaprol + calcium disodium EDTA (CaNa₂EDTA)

BAL is started before or alongside CaNa₂EDTA according to specialist protocols.

The rationale is to reduce concerns about redistribution of mobilized lead and provide complementary chelation.

Exact regimens should follow current toxicology guidance rather than older fixed schedules.

Critical EDTA Distinction

Do not confuse:

Calcium disodium EDTA

CaNa₂EDTA – a lead chelator.

with:

Disodium EDTA

Na₂EDTA – can produce profound hypocalcemia and has caused fatal medication errors.

This distinction is clinically crucial.

Lead Poisoning Without Encephalopathy

BAL is generally not preferred for routine treatment of elevated blood lead concentrations without encephalopathy.

Depending on severity, alternatives may include:

• Succimer
• CaNa₂EDTA
• Other specialist-directed strategies

Removal from the lead source remains essential.

Mercury Poisoning

BAL has historically been used for selected severe inorganic mercury poisoning when oral chelators cannot be administered.

Modern alternatives commonly include:

• Succimer
• DMPS where available

The effectiveness of chelation depends strongly on the chemical form of mercury.

Elemental Mercury

Swallowed elemental mercury is poorly absorbed from an intact gastrointestinal tract.

Therefore, simple ingestion usually does not require BAL.

In contrast:

Inhaled mercury vapor → substantial systemic absorption

and may produce:

• Cough
• Dyspnea
• Pneumonitis
• Tremor
• Neuropsychiatric abnormalities
• Renal injury

Chelation decisions are individualized.

Organic Mercury

BAL should not be routinely used for methylmercury poisoning.

Historically, there has been concern that BAL may increase redistribution of mercury toward the CNS.

Modern management of significant organic mercury poisoning generally favors other chelators when chelation is indicated.

Gold Toxicity

BAL was historically used for toxicity caused by therapeutic gold compounds.

Gold therapy could produce:

• Bone-marrow toxicity
• Dermatitis
• Renal injury
• Other systemic adverse effects

Because therapeutic gold compounds are now rarely used, this indication has become uncommon.

Other Metals

BAL has historically been proposed for poisoning involving metals such as:

• Antimony
• Bismuth
• Copper
• Nickel
• Chromium

However, evidence and preferred chelation strategies differ substantially between metals.

BAL should therefore not be assumed to be appropriate simply because an exposure involves a metal.

BAL Must NOT Be Used for Iron Poisoning

This is a major high-yield contraindication.

BAL can form a potentially toxic complex with iron.

Therefore:

Iron poisoning → do not use dimercaprol.

The specific chelator for clinically important systemic iron poisoning is deferoxamine.

Cadmium

BAL should also not be used for cadmium poisoning.

Chelation can potentially increase renal delivery of cadmium and worsen nephrotoxicity.

Management of cadmium toxicity is primarily supportive and exposure-directed.

Selenium

Dimercaprol is also not a routine treatment for selenium poisoning.

Chelation recommendations must always be metal-specific.

Peanut-Oil Formulation

Traditional BAL preparations are formulated in peanut oil.

This historically raised concern regarding use in patients with peanut allergy.

The exact excipients of the available product should be checked because formulations can vary.

For severe life-threatening poisoning, specialist assessment of the actual risk and available alternatives is appropriate rather than treating every historical formulation warning as absolute.

G6PD Deficiency

Dimercaprol may increase the risk of hemolysis in patients with glucose-6-phosphate dehydrogenase deficiency.

This is especially relevant when repeated treatment is contemplated.

The risk must be balanced against the danger of severe metal poisoning.

Renal Function

Metal–chelator complexes often depend partly on renal elimination.

Renal impairment can therefore complicate chelation by allowing:

• Metal accumulation
• Chelator accumulation
• Persistence of metal–chelator complexes

Renal function and urine output should be followed during significant treatment.

Hepatic Disease

Because BAL itself can cause adverse effects and undergoes metabolism, significant hepatic dysfunction requires additional caution.

However, life-threatening metal poisoning may still justify treatment after specialist assessment.

Adverse Effects

BAL is relatively unpleasant compared with newer chelators.

Common adverse effects include:

• Painful IM injections
• Nausea
• Vomiting
• Headache
• Burning sensations
• Paresthesias
• Anxiety or restlessness
• Lacrimation
• Salivation
• Rhinorrhea
• Sweating
• Abdominal discomfort

Symptoms often become more prominent with greater exposure.

Cardiovascular Effects

Dimercaprol may cause:

• Tachycardia
• Hypertension

These effects can be more concerning in patients who already have:

• Severe hypertension
• Cardiovascular disease
• Significant autonomic instability

Monitoring is appropriate during treatment of severe poisoning.

Injection-Site Complications

Because BAL is administered as an oily intramuscular preparation, treatment may cause:

• Significant injection pain
• Local inflammation
• Sterile abscess formation

This is another reason oral chelators are preferred when clinically appropriate.

Essential Metal Loss

Chelators are not perfectly selective.

BAL can increase elimination of physiologically important metals such as:

• Copper
• Zinc

This is more relevant with prolonged treatment.

Pregnancy

The older FDA pregnancy letter categories and older animal-data framing should not be used in isolation.

Chelation during pregnancy requires consideration of:

• Metal involved
• Maternal toxicity
• Fetal toxicity from the metal itself
• Severity and timing of exposure
• Available alternative chelators

In severe life-threatening poisoning, necessary maternal treatment should not be withheld solely because of pregnancy.

Monitoring During BAL Therapy

Important monitoring may include:

• Clinical neurologic status
• Heart rate and blood pressure
• Renal function
• Urine output
• Liver function when appropriate
• CBC
• Evidence of hemolysis
• Relevant blood or urine metal concentrations
• Injection sites

Laboratory concentrations should always be interpreted in the context of the specific metal and timing of chelation.

Transition to Oral Chelation

A common principle is:

Use parenteral BAL during the severe phase when necessary → transition to a better-tolerated oral chelator once clinically appropriate.

Prolonging BAL after the patient can safely receive an effective alternative generally adds toxicity without clear benefit.

Chelation Does Not Replace Supportive Care

Even when BAL is indicated, management may still require treatment of:

• Shock
• Dysrhythmias
• Seizures
• Electrolyte disturbances
• Hemolysis
• Acute kidney injury
• Encephalopathy

Chelation is only one component of management.

Important Modernization of the Older Source

Several older recommendations require qualification:

• BAL now has a narrower role because succimer and DMPS are often better tolerated.
• It remains particularly relevant for severe acute arsenic poisoning when oral treatment is unsuitable and for traditional management of lead encephalopathy with CaNa₂EDTA.
• BAL is not recommended for routine treatment of elevated lead levels without encephalopathy.
• It should not be routinely used for methylmercury.
• BAL should be avoided in iron poisoning.
• BAL should be avoided in cadmium poisoning.
• The exact available formulation should be checked rather than assuming every product contains identical excipients.
• Historical fixed-duration and concentration-based chelation schedules should not replace individualized toxicology guidance.
• Hemodialysis is not simply a routine method for removing BAL–metal complexes; extracorporeal therapy depends on the specific metal, clinical syndrome, and renal failure.
• Chelation decisions should be based on the specific metal and its chemical form, not merely on the presence of “heavy-metal exposure.”

Key Points

• Dimercaprol = BAL = British Anti-Lewisite.
• It is a lipid-soluble dithiol chelator administered intramuscularly.
• Its sulfhydryl groups bind selected toxic metals.
• BAL was originally developed against the arsenical warfare agent Lewisite.
• Important modern uses include selected severe acute arsenic poisoning and lead encephalopathy.
• Severe lead encephalopathy has traditionally been treated with BAL plus calcium disodium EDTA.
• Never confuse CaNa₂EDTA with disodium EDTA.
• Succimer or DMPS is often preferred when an effective oral chelator can be used.
• BAL is generally not appropriate for chronic methylmercury toxicity.
• Do not use BAL for iron poisoning.
• Do not use BAL for cadmium poisoning.
• Important adverse effects include painful injections, nausea, autonomic symptoms, tachycardia, and hypertension.
• G6PD deficiency may increase the risk of hemolysis.
• Renal function is important because metal–chelator complexes must be eliminated.
• BAL should generally be replaced by a better-tolerated effective oral chelator once the clinical situation permits.
• Chelation should be directed by the specific metal, chemical form, severity, symptoms, and appropriate toxicologic testing rather than by a generic diagnosis of heavy-metal exposure.

Toxicology – Botulinum Antitoxin

Core Concept

Botulinum antitoxin neutralizes circulating botulinum neurotoxin that has not yet entered nerve terminals.

It is used for suspected or confirmed non-infant botulism, including:

• Foodborne botulism
• Wound botulism
• Certain other systemic botulism syndromes

The major modern product for non-infant botulism is heptavalent botulism antitoxin (HBAT), which covers toxin types:

A, B, C, D, E, F, and G

The older monovalent, bivalent, and trivalent framework in the source no longer represents standard contemporary management in the United States.

Botulinum Neurotoxin Mechanism

Botulinum neurotoxin enters cholinergic nerve terminals and disrupts proteins required for acetylcholine-containing vesicles to fuse with the presynaptic membrane.

The result is:

Blocked acetylcholine release → neuromuscular transmission failure → flaccid paralysis

Autonomic cholinergic transmission may also be impaired.

Typical Clinical Pattern

Botulism classically produces:

Acute bilateral cranial neuropathies → symmetric descending weakness → respiratory paralysis

Early manifestations may include:

• Blurred vision
• Diplopia
• Ptosis
• Dilated or poorly reactive pupils
• Dysarthria
• Dysphonia
• Dysphagia
• Dry mouth

Weakness then progresses downward.

Neurologic Findings

Typical findings include:

• Symmetric descending paralysis
• Normal or reduced reflexes
• Preserved sensation
• Usually preserved mental status
• Respiratory muscle weakness

Patients may be profoundly weak while remaining fully conscious.

Respiratory Failure

The major immediate threat is respiratory muscle paralysis.

Monitor closely for:

• Weak cough
• Difficulty handling secretions
• Bulbar dysfunction
• Declining respiratory muscle strength
• Hypoventilation

Do not wait for severe hypoxemia before recognizing ventilatory failure.

Some patients require prolonged mechanical ventilation.

How Antitoxin Works

Antitoxin antibodies bind free circulating toxin.

This prevents additional toxin from attaching to nerve endings.

However:

Antitoxin cannot remove toxin that has already entered the nerve terminal.

Therefore, it generally:

• Prevents or slows further neurologic progression
• Reduces subsequent severity when given early
• Does not immediately reverse established paralysis

Recovery requires restoration of functional neuromuscular transmission.

Why Early Treatment Matters

Because antitoxin acts only against toxin that has not yet entered nerve endings:

Earlier administration provides greater potential benefit.

Treatment should therefore begin as soon as clinical botulism is reasonably suspected.

Laboratory confirmation should not delay antitoxin in a compatible clinical syndrome.

Do Not Wait for Toxin Typing

The older approach depended heavily on determining the botulinum toxin serotype.

Modern heptavalent antitoxin provides coverage against all seven recognized toxin serotypes targeted by the product.

Consequently, treatment generally does not need to wait for serotype identification.

Major Indications

Antitoxin should be considered when an adolescent or adult has a compatible syndrome such as:

• Acute bilateral cranial nerve palsies
• Descending symmetric weakness
• Bulbar dysfunction
• Respiratory muscle weakness

with an epidemiologic setting compatible with botulism.

Examples include:

• Suspected contaminated food
• Wound associated with botulism
• Injection-drug-associated wound botulism
• Other credible botulinum toxin exposure

Asymptomatic Exposure

The older source recommended antitoxin for some people who merely consumed food suspected of containing botulinum toxin.

Modern management does not routinely give antitoxin prophylactically to asymptomatic exposed individuals.

Such individuals require exposure-specific public-health guidance and monitoring.

Antitoxin is primarily used when clinical botulism is suspected.

Foodborne Botulism

Foodborne disease results from ingestion of preformed botulinum neurotoxin.

Symptoms may begin with:

• Diplopia
• Ptosis
• Blurred vision
• Dysphagia
• Dysarthria
• Dry mouth

This is followed by descending weakness.

GI symptoms can occur but are not required.

Wound Botulism

In wound botulism, Clostridium botulinum grows within a contaminated wound and produces toxin in vivo.

Management involves:

• Antitoxin
• Respiratory/supportive care
• Appropriate wound management
• Appropriate antimicrobial therapy

The wound can continue producing toxin until the infection is controlled.

Infant Botulism

Infant botulism requires a different treatment strategy.

In the United States, the preferred specific therapy for eligible infant botulism is human botulism immune globulin intravenous (BabyBIG) rather than equine HBAT.

This is an important distinction from adult and older pediatric botulism.

Laboratory Confirmation

Diagnostic specimens may include:

• Serum
• Stool
• Gastric contents
• Suspected food
• Wound material

Testing may detect:

• Botulinum toxin
• Toxigenic Clostridium organisms

However:

Specimen collection and laboratory testing should not postpone antitoxin treatment.

Differential Diagnosis

Botulism can resemble:

• Myasthenia gravis
• Guillain–Barré syndrome
• Brainstem stroke
• Tick paralysis
• Organophosphate poisoning
• Lambert–Eaton syndrome
• Diphtheritic neuropathy
• Certain shellfish or marine neurotoxin syndromes

A useful clue is:

Alert patient + bilateral cranial neuropathies + descending symmetric flaccid paralysis + preserved sensation

Antitoxin Hypersensitivity

Modern HBAT remains an equine-derived antibody product, so hypersensitivity reactions can occur.

Possible reactions include:

• Rash
• Urticaria
• Pruritus
• Bronchospasm
• Hypotension
• Anaphylaxis

Administration should therefore occur with appropriate monitoring and immediate access to anaphylaxis treatment.

Anaphylaxis Management

If clinically significant anaphylaxis occurs:

Epinephrine is first-line therapy.

Additional management may include:

• Airway support
• Oxygen
• IV fluids
• Bronchodilator treatment for persistent bronchospasm
• Other supportive measures

Antihistamines and corticosteroids should not replace epinephrine.

The older source’s extensive reliance on antihistamine/H2-blocker/steroid regimens reflects outdated anaphylaxis practice.

Serum Sickness

Because HBAT contains equine-derived proteins, delayed serum sickness can occur.

Symptoms may appear days later and include:

• Fever
• Rash
• Pruritus
• Arthralgia
• Malaise

Patients should receive appropriate follow-up instructions after antitoxin exposure.

Skin Testing

Routine horse-serum skin testing before modern botulinum antitoxin is not relied upon as a dependable predictor of anaphylaxis.

A negative skin test cannot guarantee safe administration.

Treatment of a serious suspected botulism case should not be unnecessarily delayed by outdated testing strategies.

Pregnancy

Pregnancy is not a reason to withhold indicated antitoxin.

Maternal botulism can cause life-threatening respiratory paralysis, while antitoxin acts primarily within the intravascular/extracellular compartment.

Treatment decisions should prioritize timely control of maternal disease.

Supportive Care

Antitoxin is only one component of treatment.

Supportive management may include:

• Airway protection
• Mechanical ventilation
• Aspiration prevention
• Nutritional support
• Prevention of pressure injuries
• Prevention of venous thromboembolism when appropriate
• Physical rehabilitation

Recovery can be prolonged.

Antibiotics

Antibiotics do not neutralize circulating botulinum toxin.

They may be indicated for wound botulism, where bacterial growth continues within infected tissue.

They are not routine therapy for uncomplicated foodborne botulism.

Recovery

Antitoxin does not instantly restore paralyzed muscles.

Recovery depends on restoration of neuromuscular transmission and may take:

• Weeks
• Occasionally months

Respiratory weakness can therefore persist long after circulating toxin has been neutralized.

Public-Health Role

Suspected botulism is a public-health emergency.

Public-health authorities can:

• Coordinate antitoxin access
• Arrange specialized laboratory testing
• Investigate contaminated food or common exposures
• Identify additional people at risk

Current local public-health procedures should be used rather than historical telephone numbers from older references.

Important Modernization of the Older Source

Several major updates are necessary:

• Modern non-infant treatment uses heptavalent botulism antitoxin (HBAT) rather than relying on the older A/B/E trivalent product.
• HBAT covers toxin types A through G.
• Antitoxin should be given promptly when clinical botulism is suspected; do not wait for laboratory confirmation or serotyping.
• Antitoxin neutralizes unbound toxin but does not reverse toxin already internalized by nerve terminals.
• Routine prophylactic antitoxin for an asymptomatic person who merely ate suspect food is not standard modern practice.
• Infant botulism is treated differently; in the U.S., BabyBIG is preferred for eligible infants.
• Routine horse-serum skin testing is not a reliable modern strategy for preventing antitoxin reactions.
• Modern anaphylaxis treatment prioritizes epinephrine, not antihistamines, H2 blockers, or corticosteroids.
• Product-specific instructions and current public-health guidance supersede the historical dosing schedules and telephone numbers in the source.

Key Points

• Botulinum neurotoxin prevents presynaptic acetylcholine release.
• Botulism typically produces bilateral cranial neuropathies followed by symmetric descending flaccid paralysis.
• Sensation and consciousness are generally preserved.
• Respiratory muscle paralysis is the major life-threatening complication.
• HBAT neutralizes circulating, unbound toxin.
• It cannot reverse toxin that has already entered nerve terminals.
• Give antitoxin as early as possible when clinical botulism is suspected.
• Do not delay treatment while waiting for laboratory confirmation or toxin typing.
• Modern HBAT covers botulinum toxin types A–G.
• Antitoxin does not immediately reverse established paralysis, so prolonged respiratory support may still be necessary.
• Infant botulism requires a different approach, with human botulism immune globulin (BabyBIG) used in eligible infants in the U.S.
• Wound botulism requires antitoxin plus appropriate wound and infection management.
• Equine-derived antitoxin can cause anaphylaxis and delayed serum sickness.
• Epinephrine is first-line treatment for anaphylaxis.
• Suspected botulism should prompt immediate involvement of appropriate toxicology and public-health services.

Toxicology – Black Widow Spider Antivenom

Core Concept

Black widow antivenom neutralizes circulating venom from Latrodectus spiders.

Black widow envenomation, or latrodectism, primarily causes a painful neurotoxic syndrome characterized by:

• Severe local or generalized pain
• Painful muscle spasms
• Abdominal or back rigidity
• Diaphoresis
• Nausea/vomiting
• Restlessness
• Tachycardia
• Hypertension

Antivenom can produce rapid improvement in severe systemic envenomation, but its use depends on the available formulation and the balance between benefit and hypersensitivity risk.

Mechanism of Envenomation

The major black widow venom component, α-latrotoxin, acts at presynaptic nerve terminals and causes excessive neurotransmitter release.

This produces marked autonomic and neuromuscular activity.

The result can include:

Pain → muscle spasm → autonomic hyperactivity

Severe cases may produce substantial hypertension and other systemic manifestations.

How Antivenom Works

Traditional black widow antivenom is produced from antibodies obtained from immunized horses.

These antibodies bind circulating venom components and prevent them from interacting with additional target tissues.

Antivenom therefore provides passive immunity against the venom.

It does not simply provide analgesia—it targets the venom itself.

Cross-Reactivity

Antibodies against one medically important Latrodectus species may cross-react with venom from related widow spiders.

However, actual antivenom products and availability vary considerably by country and region.

Treatment should therefore follow the specific locally available product and poison-center/toxicology guidance.

When Antivenom Is Considered

Most black widow bites do not automatically require antivenom.

Supportive treatment is sufficient for many patients.

Antivenom is generally reserved for clinically important systemic envenomation, particularly when there is:

• Severe or persistent pain despite adequate analgesia
• Severe muscle spasms
• Significant autonomic instability
• Severe hypertension
• Respiratory compromise
• Other serious systemic toxicity

Patient-specific factors and the antivenom formulation influence the decision.

Supportive Treatment

Initial management includes:

• Analgesia
• Treatment of severe muscle spasm when necessary
• Monitoring of vital signs
• Supportive respiratory care when required

The historical practice of routinely relying on calcium for black widow muscle spasms is not supported as a consistently effective treatment.

Clinical Response to Antivenom

When effective, improvement may occur relatively rapidly.

Possible responses include:

• Reduction in severe pain
• Decreased muscle spasm
• Improvement in autonomic manifestations

Persistent symptoms require reassessment of:

• Severity of envenomation
• Alternative diagnoses
• Adequacy of supportive therapy
• Whether additional antivenom is appropriate under the product-specific protocol

Major Risk – Hypersensitivity

Equine-derived antivenoms contain foreign proteins and can cause immediate hypersensitivity reactions.

Possible manifestations include:

• Urticaria
• Pruritus
• Flushing
• Angioedema
• Bronchospasm
• Hypotension
• Anaphylaxis

Administration should therefore occur in a monitored setting with the ability to recognize and treat anaphylaxis immediately.

Anaphylaxis

If anaphylaxis develops:

• Stop or pause the suspected triggering infusion as clinically appropriate.
• Assess airway, breathing, and circulation.
• Give epinephrine as first-line treatment.
• Provide oxygen and airway/ventilatory support when needed.
• Give appropriate IV fluids for hypotension.
• Use adjunctive therapies for persistent bronchospasm or other manifestations.

Antihistamines and corticosteroids are adjuncts, not substitutes for epinephrine in anaphylaxis.

This is an important modernization of the older source.

Skin Testing

Older equine-antivenom protocols commonly recommended horse-serum skin testing before treatment.

This has important limitations:

• A negative test does not reliably exclude a serious reaction.
• Testing itself can cause hypersensitivity.
• It can delay urgently needed antivenom.

Modern practice follows the instructions for the specific antivenom product rather than assuming routine skin testing is universally useful.

Delayed Serum Sickness

Equine antivenom can also produce a delayed immune-complex reaction.

Symptoms usually develop days after treatment and may include:

• Fever
• Malaise
• Rash
• Pruritus
• Arthralgia

Less commonly, more significant systemic manifestations occur.

Patients receiving equine antivenom should be informed that delayed symptoms can occur after discharge.

Pregnancy

Pregnancy does not automatically contraindicate antivenom.

Severe maternal envenomation itself can threaten both mother and fetus.

The obsolete FDA pregnancy letter categories should not be used as the primary basis for decision-making.

Treatment depends on maternal disease severity and the expected benefits and risks of the available antivenom.

Monitoring

During antivenom administration monitor:

• Heart rate
• Blood pressure
• Respiratory status
• Oxygenation
• Skin/mucosal findings
• Pain and muscle spasm
• Evidence of hypersensitivity

Continued monitoring is particularly important during administration of equine-derived products.

Key Points

• Black widow venom produces latrodectism, characterized particularly by severe pain, muscle spasm, and autonomic hyperactivity.
• α-Latrotoxin causes excessive neurotransmitter release from presynaptic terminals.
• Antivenom antibodies bind circulating venom and prevent additional toxic effects.
• Mild envenomation generally does not require antivenom.
• Antivenom is considered for significant systemic toxicity or severe symptoms inadequately controlled with supportive care.
• Equine antivenom can cause immediate hypersensitivity and delayed serum sickness.
• Epinephrine is first-line therapy for antivenom-induced anaphylaxis.
• Antihistamines and corticosteroids are only adjunctive treatments for anaphylaxis.
• Routine horse-serum skin testing is not a universally reliable modern strategy.
• Product availability and formulations vary geographically, so current product-specific guidance is essential.

Toxicology – Atropine

Core Concept

Atropine is a competitive muscarinic acetylcholine receptor antagonist.

In toxicology, its most important role is treatment of the dangerous muscarinic manifestations of cholinergic poisoning, particularly from:

• Organophosphate pesticides
• Carbamate pesticides
• Nerve agents
• Other clinically important cholinesterase inhibitors

Atropine is also used in selected cases of symptomatic bradycardia.

Mechanism of Action

Atropine competitively blocks acetylcholine at muscarinic receptors.

This decreases parasympathetic activity in organs such as the:

• Heart
• Bronchial tree
• Salivary glands
• Gastrointestinal tract
• Urinary tract
• Eyes
• Sweat glands

The clinically important toxicologic effect is:

Muscarinic receptor blockade → reduced bronchial secretions and bronchoconstriction

Muscarinic vs Nicotinic Effects

This distinction is essential in cholinergic poisoning.

Muscarinic manifestations

Atropine is effective against:

• Bronchorrhea
• Bronchospasm
• Excess salivation
• Lacrimation
• Bradycardia
• Some GI hyperactivity

Nicotinic manifestations

Atropine does not directly reverse:

• Fasciculations
• Skeletal muscle weakness
• Paralysis
• Respiratory muscle failure

Therefore, improvement in secretions does not necessarily mean the entire cholinergic syndrome has resolved.

Central Nervous System Effects

Atropine crosses the blood-brain barrier.

At sufficient exposure it can produce central antimuscarinic effects such as:

• Agitation
• Confusion
• Delirium
• Hallucinations

This differs from quaternary antimuscarinic drugs such as glycopyrrolate, which have much less CNS penetration.

Main Toxicologic Indication: Cholinergic Poisoning

Severe cholinesterase inhibitor poisoning may produce:

• Miosis
• Salivation
• Lacrimation
• Bronchorrhea
• Bronchospasm
• Vomiting
• Diarrhea
• Sweating
• Bradycardia or tachycardia
• Fasciculations
• Weakness
• Seizures
• Respiratory failure

The major immediate threat is often respiratory compromise from a combination of:

• Copious airway secretions
• Bronchoconstriction
• Respiratory muscle weakness
• CNS dysfunction

Atropine primarily treats the first two components.

Atropine Treatment Endpoint

In severe cholinergic poisoning, atropine should be titrated according to the clinical response, particularly the respiratory findings.

The important endpoint is:

Improved ventilation with substantial control of bronchial secretions and bronchospasm

Useful signs include:

• Drying of excessive pulmonary secretions
• Improved air movement
• Improved oxygenation
• Improved hemodynamic status when muscarinic effects contributed

Do Not Use Pupil Size as the Endpoint

Miosis may persist despite adequate treatment.

Therefore:

Pupil dilation is not required for successful atropinization.

Attempting to normalize pupil size can lead to unnecessary atropine administration.

Do Not Use Heart Rate Alone as the Endpoint

Tachycardia is common during atropine therapy, but it does not necessarily mean treatment should stop.

A patient may still have life-threatening bronchorrhea despite being tachycardic.

Therefore:

Pulmonary secretion control and ventilation are more important endpoints than heart rate alone.

Organophosphate Poisoning

Organophosphates inhibit acetylcholinesterase, producing accumulation of acetylcholine at:

• Muscarinic synapses
• Nicotinic synapses
• CNS cholinergic pathways

Atropine competitively blocks the muscarinic consequences of this acetylcholine excess.

It does not reactivate acetylcholinesterase.

Role of Pralidoxime

In significant organophosphate poisoning, pralidoxime may be used in addition to atropine.

The two drugs have different roles:

Atropine

Controls muscarinic manifestations, especially:

• Bronchorrhea
• Bronchospasm
• Bradycardia

Pralidoxime

Can reactivate inhibited acetylcholinesterase before irreversible enzyme “aging” occurs and may particularly help with:

• Fasciculations
• Muscle weakness
• Respiratory muscle dysfunction

Atropine should not be delayed while waiting for pralidoxime.

Carbamate Poisoning

Carbamates also inhibit acetylcholinesterase but generally bind reversibly.

Atropine remains the primary treatment for clinically important muscarinic toxicity.

The role of pralidoxime is less straightforward than in organophosphate poisoning and depends on the specific exposure and clinical circumstances.

Nerve-Agent Exposure

Nerve agents are potent organophosphorus cholinesterase inhibitors.

Severe exposure may cause rapid:

• Bronchorrhea
• Bronchospasm
• Seizures
• Fasciculations
• Paralysis
• Respiratory failure

Management may require:

• Airway and ventilatory support
• Atropine
• An oxime such as pralidoxime
• Benzodiazepines for seizures

Symptomatic Bradycardia

Atropine can increase heart rate by reducing parasympathetic influence on the:

• Sinoatrial node
• AV node

It may be appropriate for selected symptomatic bradycardias associated with poor perfusion.

However, atropine is not equally effective for every toxicologic bradycardia.

Toxicologic Bradycardias

Important causes include:

• Beta-blockers
• Calcium channel blockers
• Digoxin
• Clonidine/imidazolines
• Cholinergic agents
• Opioids

In many of these poisonings, atropine may provide little or only transient benefit.

The priority is the toxin-specific mechanism and treatment.

Examples include:

• Digoxin toxicity → digoxin immune Fab when indicated
• Severe beta-blocker/CCB toxicity → mechanism-directed cardiovascular support
• Opioid toxicity → naloxone when respiratory depression is present
• Cholinergic poisoning → atropine is directly relevant

Expected Antimuscarinic Effects

Atropine itself can produce:

• Tachycardia
• Mydriasis
• Cycloplegia
• Dry mouth
• Reduced sweating
• Flushed skin
• Reduced bowel motility
• Urinary retention

Larger exposures may cause:

• Hyperthermia
• Agitation
• Hallucinations
• Delirium

These findings represent an anticholinergic syndrome.

Hyperthermia Risk

Atropine decreases sweating.

Because sweating is important for heat dissipation, antimuscarinic therapy can increase susceptibility to hyperthermia, particularly in:

• Hot environments
• Young children
• Patients already hyperthermic
• Patients receiving other anticholinergic medications

Temperature should therefore be monitored during substantial atropine therapy.

Ophthalmic Effects

Topical atropine causes:

Mydriasis

Dilation of the pupil.

Cycloplegia

Paralysis of accommodation.

The ocular effects can persist considerably longer than atropine’s cardiovascular effects.

Possible consequences include:

• Photophobia
• Blurred near vision
• Increased intraocular pressure in susceptible patients

Angle-Closure Glaucoma

Ophthalmic antimuscarinic medications can precipitate or worsen acute angle closure in anatomically susceptible eyes.

This is particularly relevant when atropine is being used specifically as an ophthalmic medication.

In a life-threatening systemic poisoning, however, relative contraindications should not prevent necessary antidotal atropine treatment.

Systemic Absorption from Eye Drops

Atropine administered ophthalmically can be absorbed systemically.

Systemic anticholinergic effects are more concerning in:

• Children
• Older adults
• Patients receiving excessive topical medication

Possible manifestations include:

• Tachycardia
• Dry mouth
• Flushing
• Hyperthermia
• Confusion

Drug Interactions

Atropine’s antimuscarinic effects may be increased by other medications with anticholinergic properties, including certain:

• First-generation antihistamines
• Antipsychotics
• Tricyclic antidepressants
• Antiparkinsonian drugs
• Antispasmodic medications

Combining substantial anticholinergic burdens can increase the risk of:

• Delirium
• Hyperthermia
• Urinary retention
• Ileus
• Tachycardia

The older source’s description of sympathomimetics simply “potentiating atropine” is an oversimplification; rather, their physiologic effects can overlap, particularly tachycardia and hyperthermia.

Atropine Toxicity

Excess atropine produces an antimuscarinic toxidrome.

Typical findings include:

• Mydriasis
• Dry mucous membranes
• Dry skin
• Flushing
• Tachycardia
• Hyperthermia
• Urinary retention
• Reduced bowel sounds
• Agitation
• Delirium
• Hallucinations

Severe poisoning can cause marked CNS and cardiovascular abnormalities.

Physostigmine and Atropine Toxicity

Physostigmine is a centrally active acetylcholinesterase inhibitor that can reverse selected severe pure antimuscarinic delirium.

However, it is not automatically appropriate whenever atropine-like symptoms occur.

Before considering it, clinicians must exclude important contraindications and alternative causes, particularly:

• Sodium-channel-blocking poisoning
• Significant QRS widening
• Certain conduction abnormalities
• Mixed overdose

Supportive care remains fundamental.

Atropine Administration in Severe Cholinergic Poisoning

Severe organophosphate poisoning may require very large cumulative quantities of atropine compared with ordinary bradycardia treatment.

The principle is more important than memorizing a fixed maximum:

Escalate atropine rapidly enough to control life-threatening muscarinic pulmonary toxicity.

Once adequate control is achieved, ongoing therapy may be required because the toxicant can persist much longer than atropine.

Exact dosing should follow current poison-center or critical-care protocols.

Recurrent Cholinergic Toxicity

Atropine’s clinical effect may wear off while the cholinesterase inhibitor remains active.

Therefore, patients can develop recurrent:

• Bronchorrhea
• Bronchospasm
• Bradycardia
• Other muscarinic manifestations

Continued reassessment is essential.

Monitoring

During significant atropine treatment, monitor:

• Airway
• Respiratory effort
• Pulmonary secretions
• Oxygenation
• Heart rate and rhythm
• Blood pressure
• Temperature
• Mental status
• Bowel and urinary function when relevant

In cholinergic poisoning, also monitor for:

• Fasciculations
• Progressive weakness
• Respiratory muscle failure
• Recurrent secretions

Pregnancy

The historical FDA pregnancy categories such as Category C are obsolete.

When atropine is required for a serious maternal indication, including significant cholinergic poisoning, pregnancy should not prevent necessary treatment.

Maternal stabilization remains the priority.

Common Pitfalls

Stopping atropine because tachycardia develops

Tachycardia does not prove that pulmonary muscarinic toxicity has resolved.

Waiting for the pupils to dilate

Pupil size is not the treatment endpoint.

Expecting atropine to reverse muscle weakness

Nicotinic neuromuscular dysfunction is not directly reversed by atropine.

Giving atropine but ignoring ventilation

Patients with severe organophosphate poisoning can still require airway and ventilatory support.

Using a fixed maximum dose in severe poisoning

Massive cholinergic toxicity may require unusually large cumulative atropine exposure.

Assuming every toxicologic bradycardia will respond

Many cardiotoxic poisons require specific therapies beyond atropine.

Important Modernization of the Older Source

Several points from the original material require updating:

• Atropine is best described specifically as an antimuscarinic, rather than broadly as an “anticholinergic antidote.”
• Its most important endpoint in cholinergic poisoning is control of bronchorrhea/bronchospasm and improvement in ventilation, not normalization of pupil size or heart rate.
• Atropine does not treat nicotinic weakness or paralysis.
• Severe organophosphate poisoning may require very large amounts, with treatment guided by clinical response rather than a conventional maximum dose.
• Pralidoxime has a complementary role in significant organophosphate poisoning.
• Atropine is not reliably effective for all poison-induced bradycardias.
• Routine atropine as a premedication for pediatric procedural sedation is not standard modern practice.
• FDA pregnancy letter categories are obsolete.
• Sympathomimetics do not simply “potentiate atropine”; rather, several physiologic effects can overlap.
• Relative contraindications to atropine should not prevent its use when treating life-threatening cholinergic poisoning.

Key Points

• Atropine is a competitive muscarinic acetylcholine receptor antagonist.
• It has little direct effect at nicotinic receptors.
• Its major toxicologic use is treatment of muscarinic cholinergic toxicity.
• It is especially important for bronchorrhea and bronchospasm caused by organophosphates, carbamates, and nerve agents.
• The major treatment endpoint is adequate ventilation with control of excessive pulmonary secretions.
• Do not titrate atropine to pupil size.
• Do not stop treatment merely because tachycardia develops.
• Atropine does not directly reverse fasciculations, skeletal muscle weakness, or paralysis.
• Pralidoxime complements atropine in significant organophosphate poisoning by targeting the inhibited acetylcholinesterase mechanism.
• Severe cholinergic poisoning may require unusually large cumulative atropine exposure.
• Atropine can treat selected symptomatic bradycardias, but many toxicologic bradycardias require toxin-specific treatment.
• Excess atropine causes an antimuscarinic syndrome with tachycardia, mydriasis, dry skin/mucosa, urinary retention, hyperthermia, and delirium.
• Significant cholinergic poisoning requires continued monitoring because toxicity may recur after atropine’s effects diminish.

Toxicology – Adenosine

Core Concept

Adenosine is an extremely short-acting antiarrhythmic medication used primarily to terminate certain regular supraventricular tachycardias (SVTs) that depend on the AV node for maintenance.

Its extremely short duration of action makes both its therapeutic effects and most adverse effects brief.

In toxicology, adenosine may occasionally be useful for a true AV-node-dependent SVT, but it does not treat the underlying poisoning.

Main Clinical Role

Adenosine is most useful for:

• Regular, narrow-complex SVT
• AV nodal reentrant tachycardia (AVNRT)
• AV reentrant tachycardia (AVRT) involving an accessory pathway when the rhythm is appropriate for adenosine
• Selected regular monomorphic wide-complex tachycardias when SVT with aberrancy is being considered and use is clinically appropriate

Vagal maneuvers are generally attempted first in a stable patient with an appropriate regular SVT.

Mechanism of Action

Adenosine acts primarily at A1 adenosine receptors in cardiac nodal tissue.

This produces:

• Increased potassium conductance
• Reduced calcium-dependent activity
• Hyperpolarization of AV nodal cells
• Slowing of AV nodal conduction
• Increased AV nodal refractoriness

The key clinical result is:

Transient AV nodal block

If a tachycardia requires the AV node as part of its reentry circuit, briefly interrupting AV conduction can terminate the rhythm.

Why the Effect Is So Brief

Adenosine is rapidly taken up and metabolized by cells in blood and vascular tissues.

Its plasma half-life is only a few seconds.

Therefore:

• It must reach the circulation rapidly.
• Its therapeutic effect occurs almost immediately.
• Most adverse effects resolve rapidly.
• Recurrent tachycardia can occur if the underlying trigger persists.

Adenosine and Toxicologic Tachycardia

Adenosine should not be viewed as a general treatment for tachycardia caused by poisoning.

Many toxicologic tachycardias are compensatory or driven by persistent mechanisms such as:

• Sympathetic stimulation
• Hyperthermia
• Hypovolemia
• Hypoxia
• Metabolic acidosis
• Anticholinergic effects
• Withdrawal

In these situations, slowing the AV node does not correct the underlying problem.

The priority is to treat the toxicologic mechanism.

Theophylline Toxicity

Theophylline deserves special attention.

Theophylline is a methylxanthine and adenosine-receptor antagonist, so it can reduce the effectiveness of adenosine.

Theophylline poisoning commonly causes:

• Marked sinus tachycardia
• Supraventricular dysrhythmias
• Tremor
• Vomiting
• Hypokalemia
• Hyperglycemia
• Seizures

Therefore, persistent tachycardia in theophylline poisoning should not automatically be treated as an adenosine-responsive SVT.

Caffeine

Caffeine is also a methylxanthine and antagonizes adenosine receptors.

Recent substantial caffeine exposure may therefore reduce responsiveness to adenosine.

This interaction is especially relevant with large caffeine exposures or toxicity.

Dipyridamole

Dipyridamole can potentiate adenosine’s effects by interfering with cellular adenosine uptake.

This can produce a stronger or more prolonged response than expected.

Medication history is therefore important before administration.

Carbamazepine

Carbamazepine can enhance AV nodal conduction suppression and may increase the risk of excessive bradycardia or AV block when combined with adenosine.

Extra caution is appropriate when significant carbamazepine exposure is suspected.

What Adenosine Does NOT Usually Convert

Adenosine generally does not terminate rhythms whose circuit does not depend on the AV node.

Examples include:

• Atrial fibrillation
• Atrial flutter
• Most atrial tachycardias
• Sinus tachycardia
• Ventricular tachycardia

However, transient AV nodal blockade may sometimes expose underlying atrial activity and thereby help clarify the diagnosis.

Atrial Flutter

Adenosine may transiently block conduction through the AV node without eliminating the atrial flutter circuit.

The ECG may briefly reveal flutter waves more clearly.

Thus:

Adenosine may reveal atrial flutter without actually treating the underlying flutter.

Atrial Fibrillation

Adenosine does not terminate atrial fibrillation.

Particular caution is required when atrial fibrillation occurs with an accessory pathway, such as pre-excited atrial fibrillation, because AV nodal blockade can be dangerous.

An irregular wide-complex tachycardia should therefore not be reflexively treated with adenosine.

WPW and Accessory Pathways

The older source broadly lists Wolff-Parkinson-White syndrome as an indication, but this requires important clarification.

Adenosine can terminate orthodromic AVRT, in which the AV node forms part of the reentry circuit.

However:

Pre-excited atrial fibrillation is different and AV nodal blocking agents should be avoided.

Therefore, the rhythm itself—not simply the presence of WPW—determines whether adenosine is appropriate.

Regular vs Irregular Tachycardia

A high-yield distinction is:

Regular narrow-complex tachycardia

Adenosine may be appropriate if AV-node-dependent SVT is suspected.

Regular monomorphic wide-complex tachycardia

Adenosine may sometimes be considered in carefully selected stable cases.

Irregular wide-complex tachycardia

Do not routinely give adenosine; consider atrial fibrillation with pre-excitation, polymorphic VT, and other dangerous rhythms.

Unstable Tachycardia

Adenosine should not delay definitive treatment in a patient with hemodynamic instability.

Important instability findings include:

• Hypotension
• Shock
• Ischemic chest discomfort
• Acute heart failure
• Altered mental status from poor perfusion

An unstable tachyarrhythmia generally requires immediate synchronized cardioversion when appropriate, rather than repeated attempts at pharmacologic conversion.

Diagnostic Value

Because adenosine briefly suppresses AV nodal conduction, it can sometimes help distinguish:

• AV-node-dependent SVT
• Atrial flutter
• Certain atrial tachycardias

Continuous ECG recording during administration is useful because the diagnostic changes may last only seconds.

Expected Transient Effects

Patients should be warned, when circumstances allow, that adenosine can produce a sudden and unpleasant sensation.

Common transient symptoms include:

• Flushing
• Chest pressure or tightness
• Dyspnea
• Lightheadedness
• Nausea
• Sense of impending doom

These symptoms usually resolve rapidly because the drug disappears from the circulation within seconds.

Transient Bradycardia and AV Block

Adenosine intentionally produces transient AV nodal suppression.

The monitor may briefly show:

• Marked bradycardia
• AV block
• A short pause
• Transient asystole

This can look dramatic but usually resolves almost immediately.

Resuscitation equipment should nevertheless be readily available.

Bronchospasm

Adenosine can provoke bronchoconstriction.

Greater caution is warranted in patients with:

• Active bronchospasm
• Significant reactive airway disease
• Severe asthma

Clinically important bronchospasm is uncommon but potentially serious.

Major Contraindications / Situations Requiring Avoidance

Important situations include:

• Second-degree AV block without a functioning pacemaker
• Third-degree AV block without a functioning pacemaker
• Significant sinus-node dysfunction without pacing
• Irregular wide-complex tachycardia
• Pre-excited atrial fibrillation
• Significant active bronchospasm

Clinical context and ECG interpretation remain essential.

Administration Principle

Because adenosine disappears from circulation extremely rapidly, it must be delivered as a rapid IV bolus followed immediately by a flush.

A proximal peripheral IV can be used effectively; a central venous line is not routinely required.

This corrects the older source’s implication that adenosine needs to be administered through a central line.

Monitoring During Administration

Use:

• Continuous ECG monitoring
• Blood pressure monitoring
• Clinical observation
• Appropriate resuscitation equipment

A rhythm strip should ideally capture the period before, during, and after administration.

Pediatric Use

Adenosine is well established in modern pediatric resuscitation practice for appropriate SVT.

This differs from the older source’s statement that adequate pediatric evidence was lacking.

Pediatric administration is weight-based and should follow current pediatric resuscitation protocols.

Pregnancy

The old FDA pregnancy-letter categories such as Category C are obsolete.

Adenosine has an extremely short half-life and is used clinically during pregnancy when treatment of an appropriate SVT is necessary.

Pregnancy does not automatically preclude its use.

Failure of Adenosine

If an apparent SVT does not terminate, reconsider:

• Was the medication delivered rapidly enough?
• Is the rhythm actually AV-node dependent?
• Is this sinus tachycardia?
• Is it atrial flutter?
• Is it atrial tachycardia?
• Could this be ventricular tachycardia?
• Is a methylxanthine such as theophylline antagonizing adenosine?
• Is an ongoing toxicologic stimulus continuously recreating the rhythm?

Repeated treatment should not substitute for reassessing the ECG diagnosis.

Adenosine in Poisoning

In toxicology, always ask:

Is this a primary reentrant SVT, or is the tachycardia an expected physiologic consequence of the poison?

For example:

• Stimulant toxicity → control sympathetic excess and hyperthermia.
• Anticholinergic toxicity → treat the underlying syndrome.
• Theophylline toxicity → treat theophylline poisoning.
• Hypovolemia → restore appropriate circulating volume.
• Hypoxia → correct oxygenation/ventilation.
• Metabolic acidosis → identify and treat the cause.

Suppressing the heart rate without correcting the underlying process may provide little benefit and can sometimes be harmful.

Important Modernization of the Older Source

Several points require updating:

• Adenosine is not a general antidote for toxicologic tachycardia.
• Its principal role is AV-node-dependent reentrant SVT.
• A central IV line is not required; rapid administration through an appropriate peripheral line is standard.
• Pediatric use is now well established.
• FDA pregnancy letter categories are obsolete.
• WPW alone is not an indication; the specific rhythm determines whether adenosine is appropriate.
• Adenosine should be avoided in pre-excited atrial fibrillation.
• It does not normally convert atrial fibrillation or atrial flutter.
• Unstable tachyarrhythmias should receive appropriate immediate electrical management rather than allowing adenosine attempts to delay definitive treatment.

Key Points

• Adenosine is an ultra-short-acting AV nodal blocking antiarrhythmic.
• Its main therapeutic target is AV-node-dependent reentrant SVT, particularly AVNRT and appropriate AVRT.
• Its half-life is only a few seconds.
• It transiently slows or blocks AV nodal conduction.
• It does not treat ordinary sinus tachycardia caused by poisoning.
• Atrial flutter and atrial fibrillation generally do not convert with adenosine.
• Adenosine can sometimes transiently reveal atrial activity and aid rhythm diagnosis.
• Theophylline and caffeine antagonize adenosine.
• Dipyridamole potentiates adenosine.
• Use caution with significant conduction disease and bronchospastic disease.
• Avoid routine adenosine in an irregular wide-complex rhythm, particularly possible pre-excited atrial fibrillation.
• WPW-associated orthodromic AVRT may respond, but pre-excited AF is a fundamentally different situation.
• Administration requires a rapid IV bolus followed immediately by a flush.
• A central line is not routinely necessary.
• Brief flushing, chest discomfort, dyspnea, and a sensation of impending doom are common but usually disappear within seconds.
• Continuous ECG monitoring and resuscitation capability should be available.
• In poisoning, always treat the underlying toxicologic mechanism rather than treating the heart rate alone.

Toxicology – Activated Charcoal

Core Concept

Activated charcoal is a gastrointestinal decontamination agent that adsorbs many drugs and chemicals within the GI tract, reducing the amount available for systemic absorption.

It can be used in two distinct ways:

• Single-dose activated charcoal (SDAC) → attempts to reduce absorption after selected acute ingestions.
• Multiple-dose activated charcoal (MDAC) → enhances elimination of a small group of toxins after absorption.

Activated charcoal is not routinely indicated for every overdose.

Adsorption, Not Absorption

Activated charcoal works by adsorption.

This means toxic molecules attach to the charcoal’s enormous porous surface rather than being absorbed into the charcoal itself.

The resulting:

Charcoal–toxin complex → remains within GI tract → passes through stool

This decreases gastrointestinal availability of the toxin.

Why Activated Charcoal Works

Activated charcoal is specially processed to create:

• Extensive microscopic pores
• Very large surface area
• Numerous binding sites for organic molecules

Binding is strongest for many relatively large, nonpolar or poorly water-soluble organic compounds.

Small, highly ionized substances are generally less effectively adsorbed.

Single-Dose Activated Charcoal

The purpose of SDAC is to:

Bind toxin still present in the GI tract → reduce subsequent systemic absorption

It is most useful when:

• The ingestion is potentially clinically important.
• The substance is well adsorbed by charcoal.
• Administration occurs reasonably soon after ingestion.
• The patient’s airway is safe.

The potential benefit generally decreases as time passes because progressively more toxin has already been absorbed.

Timing

Activated charcoal provides its greatest theoretical benefit when given early after ingestion, particularly within approximately the first hour.

However, time alone should not determine its use.

Later administration may occasionally be considered when absorption is delayed, such as with:

• Extended-release preparations
• Enteric-coated products
• Drugs that slow gastrointestinal motility
• Very large ingestions
• Substances capable of forming pharmacobezoars

Therefore:

Charcoal should be selected according to the toxicant, formulation, timing, clinical condition, and aspiration risk—not simply because an overdose occurred.

Substances Commonly Adsorbed

Activated charcoal adsorbs many clinically important drugs, including various:

• Antidepressants
• Antipsychotics
• Anticonvulsants
• Acetaminophen
• Salicylates
• Theophylline
• Cardiovascular medications
• Sedative medications
• Antihistamines

However, charcoal adsorption varies between substances.

Important Substances Poorly Adsorbed

A useful mnemonic is:

PHAILS

• P – Pesticides? (not a reliable component of the mnemonic because many organic pesticides can actually bind charcoal)
• H – Hydrocarbons
• A – Alcohols
• I – Iron
• L – Lithium
• S – Strong acids/alkalis

A more reliable approach is to remember the major groups directly.

Activated charcoal is generally ineffective or inappropriate for:

• Lithium
• Iron
• Potassium
• Methanol
• Ethylene glycol
• Ethanol
• Isopropanol
• Strong acids
• Strong alkalis
• Many simple inorganic ions

These substances are either poorly adsorbed or present other reasons why charcoal is inappropriate.

Toxic Alcohols

Activated charcoal has essentially no useful role for:

• Methanol
• Ethylene glycol
• Isopropanol
• Ethanol

These small alcohol molecules are poorly adsorbed and are rapidly absorbed.

Management instead depends on the particular alcohol and may involve:

• Supportive care
• Fomepizole for methanol/ethylene glycol
• Correction of metabolic abnormalities
• Hemodialysis in selected severe cases

Iron

Activated charcoal does not effectively adsorb iron.

Therefore, charcoal should not be relied upon after significant iron ingestion.

Selected severe iron ingestions may instead require:

• Supportive management
• Whole-bowel irrigation in appropriate circumstances
• Deferoxamine for significant systemic toxicity

Lithium

Lithium is a small ion and is poorly adsorbed by charcoal.

Activated charcoal therefore has no meaningful role for an isolated lithium ingestion.

However, if a mixed overdose contains lithium plus another charcoal-adsorbable drug, charcoal may potentially benefit the other substance, not the lithium.

Caustic Ingestion

Activated charcoal is generally inappropriate after strong acid or alkali ingestion.

Reasons include:

• Poor therapeutic benefit
• Vomiting/aspiration risk
• Potential interference with endoscopic evaluation
• Failure to prevent direct tissue injury

Management emphasizes airway assessment, supportive care, and appropriate evaluation of caustic injury.

Hydrocarbon Ingestion

Charcoal is generally avoided after isolated hydrocarbon ingestion.

The major danger is often:

Aspiration → chemical pneumonitis

Charcoal adds aspiration risk while offering limited clinical benefit for many hydrocarbons.

Airway Protection

The most important safety consideration is aspiration.

Activated charcoal should generally not be administered to a patient who cannot reliably protect their airway unless the airway has already been secured for independent clinical reasons.

High-risk findings include:

• Significant CNS depression
• Recurrent seizures
• Severe agitation
• Repeated vomiting
• Loss of protective airway reflexes

Charcoal aspiration can produce severe pulmonary injury.

Important Airway Principle

Do not intubate a patient solely to administer activated charcoal unless the overall clinical situation independently justifies airway control.

The potential benefit of charcoal must outweigh the risks of both the procedure and aspiration.

Contraindications and Situations to Avoid Charcoal

Activated charcoal should generally be avoided or used only after specialist consideration when there is:

• Unprotected airway
• High aspiration risk
• Gastrointestinal obstruction
• Ileus
• Suspected GI perforation
• Significant caustic ingestion
• Isolated hydrocarbon ingestion with substantial aspiration potential
• A substance known not to bind meaningfully to charcoal

MDAC particularly requires adequate gastrointestinal motility.

Adverse Effects

The most common problems are gastrointestinal.

Possible adverse effects include:

• Nausea
• Vomiting
• Constipation
• Abdominal distension

Less common but serious complications include:

• Aspiration pneumonitis
• Airway obstruction from aspirated charcoal
• Ileus
• Charcoal bezoar
• Bowel obstruction
• Rare gastrointestinal perforation

Risk increases when repeated doses are used or GI motility is impaired.

Charcoal Aspiration

Pulmonary aspiration is the most clinically important complication.

It may cause:

• Hypoxemia
• Pneumonitis
• Airway obstruction
• Severe respiratory failure

The risk-benefit assessment should therefore occur before charcoal administration, not after the patient becomes sedated or develops seizures.

Cathartics

Older practice commonly combined charcoal with:

• Sorbitol
• Magnesium-containing cathartics
• Other laxatives

Routine cathartic administration is no longer recommended.

They have not demonstrated meaningful improvement in poisoning outcomes and may cause:

• Diarrhea
• Dehydration
• Electrolyte abnormalities

Repeated cathartic administration is particularly inappropriate.

Multiple-Dose Activated Charcoal

MDAC differs fundamentally from a second dose given simply because gastrointestinal absorption is prolonged.

The purpose of true MDAC is to:

Increase systemic elimination of selected toxins

It may work by:

• Interrupting enterohepatic recirculation
• Binding drug secreted into the intestinal lumen
• Maintaining a concentration gradient that promotes movement of drug from blood toward the gastrointestinal tract

This phenomenon is sometimes described as gastrointestinal dialysis.

Classic MDAC Drugs

The major substances for which MDAC has an established toxicokinetic role can be remembered as:

ABCD

• A – not traditionally included
• B – Barbiturates, especially phenobarbital
• C – Carbamazepine
• D – Dapsone

And importantly:

• Quinine
• Theophylline

A practical high-yield list is therefore:

Carbamazepine – Dapsone – Phenobarbital – Quinine – Theophylline

Phenobarbital

MDAC can increase phenobarbital elimination.

It may be considered in significant poisoning when:

• Toxicity is substantial
• GI motility is adequate
• The airway is protected
• The anticipated benefit outweighs aspiration and GI risks

Carbamazepine

Carbamazepine is particularly relevant because large overdoses can cause:

• Delayed absorption
• CNS depression
• Seizures
• Anticholinergic effects
• QRS widening
• Dysrhythmias

MDAC can enhance elimination in significant poisoning.

Severe poisoning may additionally require extracorporeal treatment in selected circumstances.

Dapsone

Dapsone can produce:

• Methemoglobinemia
• Hemolysis
• Recurrent toxicity

Its metabolites undergo enterohepatic circulation.

MDAC can help interrupt this recycling and may be useful in significant poisoning.

Theophylline

MDAC can substantially increase theophylline elimination.

Severe theophylline poisoning may produce:

• Persistent vomiting
• Tachycardia
• Hypokalemia
• Hyperglycemia
• Seizures
• Dysrhythmias

Extracorporeal removal may also be required in severe cases.

Quinine

MDAC can increase quinine elimination.

Quinine toxicity may produce:

• Tinnitus
• Hearing abnormalities
• Visual disturbances
• Hypotension
• Dysrhythmias

Its use must still be balanced against the risks of repeated charcoal administration.

Not Every Extended-Release Ingestion Needs MDAC

This distinction is important.

A later or additional charcoal dose intended to capture drug that is still being absorbed is not necessarily the same as MDAC used for enhanced systemic elimination.

Extended-release formulations may sometimes justify additional GI decontamination strategies, but this depends on:

• Drug involved
• Amount
• Timing
• GI function
• Clinical course

Whole-bowel irrigation may sometimes be considered instead for selected extended-release or poorly charcoal-adsorbed substances.

Drug Interactions

Activated charcoal can adsorb medications administered orally.

This includes:

• Therapeutic drugs
• Oral antidotes
• Other necessary medications

MDAC may also increase elimination of some medications already present systemically.

Therefore, medication timing and route should be considered when charcoal is being used.

Pregnancy

Activated charcoal is not systemically absorbed in meaningful amounts.

Pregnancy itself is therefore not generally considered a contraindication when charcoal is otherwise clinically indicated.

The same fundamental risk-benefit assessment applies, particularly regarding:

• Aspiration
• Maternal stability
• Toxicant severity

Children

Children can receive activated charcoal when genuinely indicated, but particular attention should be given to:

• Aspiration risk
• Ability to cooperate
• Vomiting
• Airway size
• Fluid/electrolyte complications from inappropriate cathartic use

Routine charcoal after every pediatric ingestion is not appropriate.

Older Adults

Older patients may have:

• Reduced GI motility
• Greater aspiration risk
• Multiple medications
• Increased susceptibility to bowel complications

MDAC can also interfere with or increase elimination of necessary therapeutic medications.

Monitoring During Charcoal Therapy

Monitor for:

• Vomiting
• Abdominal distension
• Bowel function
• Respiratory deterioration
• Aspiration
• Mental-status changes

During MDAC, reassess whether:

• GI motility remains adequate
• Toxicity is improving
• Continued charcoal remains beneficial
• Complications are developing

When to Stop MDAC

There is no universal fixed duration appropriate for every poisoning.

Treatment should be individualized according to:

• Clinical improvement
• Toxicant concentrations when useful
• Expected toxicokinetics
• GI function
• Development of complications
• Availability of more effective elimination methods

Activated Charcoal vs Whole-Bowel Irrigation

These techniques work differently.

Activated Charcoal

Adsorbs selected chemicals.

Whole-Bowel Irrigation

Physically moves gastrointestinal contents through the bowel.

Whole-bowel irrigation may be considered for selected situations such as:

• Certain sustained-release preparations
• Iron
• Lithium
• Drug packets

The appropriate method depends on the substance and clinical situation.

Activated Charcoal vs Hemodialysis

Charcoal primarily acts within the gastrointestinal tract.

Hemodialysis removes suitable toxins from the bloodstream.

Some severe poisonings may involve both gastrointestinal decontamination and extracorporeal elimination, depending on the toxicant and timing.

Important Modernization of the Older Source

Several recommendations in the original material reflect older toxicology practice.

Modern management does not support:

• Giving charcoal routinely for nearly every poisoning
• Automatically giving charcoal merely because symptoms are present late after ingestion
• Routine cathartics with the first dose
• Repeated cathartic administration
• Automatic redosing after vomiting
• Routine repeated charcoal for broad categories of overdoses
• Fixed MDAC schedules without individualized reassessment

Current practice uses activated charcoal selectively, based on anticipated benefit versus aspiration and gastrointestinal risk.

Key Points

• Activated charcoal adsorbs many drugs in the GI tract and reduces their availability for absorption.
• It is most useful when given relatively early after a clinically important, charcoal-adsorbable ingestion.
• Benefit generally declines as time from ingestion increases.
• Delayed absorption may occasionally justify later consideration.
• Charcoal does not effectively adsorb lithium, iron, potassium, or toxic alcohols.
• It is generally inappropriate for strong caustics and isolated hydrocarbon exposures.
• The major complication is pulmonary aspiration.
• An unprotected airway with impaired consciousness is a major contraindication.
• Routine cathartics are no longer recommended.
• MDAC is used for enhanced elimination, not simply because an overdose is severe.
• High-yield MDAC substances are carbamazepine, dapsone, phenobarbital, quinine, and theophylline.
• MDAC should not be used when significant ileus or bowel obstruction is present.
• Activated charcoal can adsorb orally administered therapeutic medications and antidotes.
• Whole-bowel irrigation and hemodialysis are fundamentally different techniques and may be preferable for particular toxins.
• Modern toxicology favors selective charcoal use based on toxicant, timing, formulation, airway safety, GI function, and expected clinical benefit rather than routine administration.